US20060229685A1 - Method and apparatus for treatment of gastro-esophageal reflux disease (GERD) - Google Patents

Method and apparatus for treatment of gastro-esophageal reflux disease (GERD) Download PDF

Info

Publication number
US20060229685A1
US20060229685A1 US11/450,202 US45020206A US2006229685A1 US 20060229685 A1 US20060229685 A1 US 20060229685A1 US 45020206 A US45020206 A US 45020206A US 2006229685 A1 US2006229685 A1 US 2006229685A1
Authority
US
United States
Prior art keywords
small intestine
stimulation
patient
duodenum
pancreas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/450,202
Inventor
Mark Knudson
Timothy Conrad
Luke Evnin
Katherine Tweden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reshape Lifesciences Inc
Original Assignee
Knudson Mark B
Conrad Timothy R
Evnin Luke B
Tweden Katherine S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knudson Mark B, Conrad Timothy R, Evnin Luke B, Tweden Katherine S filed Critical Knudson Mark B
Priority to US11/450,202 priority Critical patent/US20060229685A1/en
Publication of US20060229685A1 publication Critical patent/US20060229685A1/en
Assigned to RESHAPE LIFESCIENCES INC. reassignment RESHAPE LIFESCIENCES INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: ENTEROMEDICS INC.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36007Applying electric currents by contact electrodes alternating or intermittent currents for stimulation of urogenital or gastrointestinal organs, e.g. for incontinence control
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/05Electrodes for implantation or insertion into the body, e.g. heart electrode
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/05Electrodes for implantation or insertion into the body, e.g. heart electrode
    • A61N1/0551Spinal or peripheral nerve electrodes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/321Electromedical belts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/36053Implantable neurostimulators for stimulating central or peripheral nerve system adapted for vagal stimulation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/3606Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/3606Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
    • A61N1/36071Pain

Definitions

  • This invention pertains to the field of treatment of gastro-esophageal reflux disease (GERD).
  • GFD gastro-esophageal reflux disease
  • Gastro-esophageal reflux is a physical condition in which stomach acids reflux, or flow back from the stomach into the esophagus. Frequent reflux episodes may result in a more severe problem known as gastro-esophageal reflux disease (GERD).
  • GERD gastro-esophageal reflux disease
  • GERD is the most common form of dyspepsia, being present in approximately 40% of adults in the United States on an intermittent basis and some 10% on a daily basis as described in U.S. Pat. No. 6,098,629 Johnson et al., dated Aug. 8, 2000.
  • dyspepsia As indicated in Johnson et al., dyspepsia, or heartburn is defined as a burning sensation or discomfort behind the breastbone or sternum and is the most common symptom of GERD.
  • Other symptoms of GERD include dysphasia, odynophagia, hemorrhage, water brash and pulmonary manifestations such as asthma, coughing, or intermittent wheezing due to acid aspiration.
  • GERD is generally considered to be the result of a motility disorder which permits the abnormal and prolonged exposure of the esophageal lumen to acidic gastric contents.
  • Hunt “The Relationship between the Control of pH and Healing and Symptom Relief in Gastro-Oesophageal Reflux Disease”, Ailment Pharmacol Ther., 9 (Suppl. 1) pp. 3-7 (1995).
  • Many factors are believed to contribute to the onset of GERD. These include transient lower esophageal sphincter (LES) relaxations, decreased LES resting tone, delayed stomach emptying and an ineffective esophageal clearance.
  • LES transient lower esophageal sphincter
  • Treatments for GERD include lifestyle changes such as weight loss, avoidance of certain foods (e.g., coffee, caffeine, alcohol, chocolate) that exacerbate the symptoms of GERD and avoidance of excessive bending. Elevation of the head of a patient's bed helps prevent nocturnal reflux. While these avoidance strategies may be helpful there is relatively little data pointing to the efficacy of lifestyle modification for the treatment of GERD.
  • lifestyle changes such as weight loss, avoidance of certain foods (e.g., coffee, caffeine, alcohol, chocolate) that exacerbate the symptoms of GERD and avoidance of excessive bending. Elevation of the head of a patient's bed helps prevent nocturnal reflux. While these avoidance strategies may be helpful there is relatively little data pointing to the efficacy of lifestyle modification for the treatment of GERD.
  • Certain medications used for treatment of GERD have been administered for years with varying success.
  • Conventional antacids such as Tums® and Rolaids® may, in some patients, produce short-term relief but often have side effects including diarrhea and constipation.
  • H 2 -receptor antagonists which control gastric acid secretion in the basal state
  • proton pump inhibitors which control meal-stimulated acid secretion
  • Surgery treatments are also known for the treatment of GERD and include techniques for bulking the lower esophageal sphincter such as techniques described in U.S. Pat. No. 6,098,629 Johnson et al, Aug. 8, 2000.
  • Other surgical techniques include placement of pacemakers for stimulating muscle contractions in the esophageal sphincter, the stomach muscles or in the pyloric valve.
  • U.S. Pat. No. 6,104,955 to Bourgeois U.S. Pat. No. 5,861,014 to Familoni.
  • GERD GERD continues to be a serious disease proving to be difficult to treat by any of the foregoing prior art techniques.
  • One inventive aspect of the present disclosure relates to methods and devices for treating GERD by stimulating the duodenum of a patient to accelerate gastric emptying.
  • a method and apparatus for treating gastro-esophageal reflux disease of a patient.
  • the method includes stimulating a body organ to accelerate a discharge of contents from a duodenum of a patient to thereby encourage discharge of contents from a stomach of the patient across a pyloric valve of the patient and into the duodenum.
  • the apparatus of the invention includes a signal generator for generating a stimulation signal.
  • a conductor electrically connects the signal generator to the body organ to accelerate a discharge of contents from the duodenum of the patient to encourage gastric emptying.
  • FIG. 1 is a schematic representation of a gastric-emptying feedback loop with a patient-controlled stimulator for stimulating an organ of the loop;
  • FIG. 2 is a view similar to FIG. 1 with an automatic controller replacing the patient-controller of FIG. 1 and with feedback circuits to the automatic controller schematically represented.
  • a gastric emptying feedback loop is shown schematically for ease of illustration.
  • the feedback loop illustrates a patient's stomach S which is provided with food from the esophagus E.
  • a lower esophageal sphincter LES is shown positioned between the esophagus E and the stomach S.
  • the lower esophageal sphincter normally provides control of reflux of stomach contents into the esophagus E.
  • the stomach discharges into the superior duodenum D which is an upper portion of the intestines.
  • the superior duodenum D and the stomach S are separated by a pyloric valve PV which opens to permit gastric emptying from the stomach into the duodenum D.
  • nerve paths N providing signal flow paths from both the superior duodenum D and the stomach S to the brain B.
  • An efferent Vagal nerve VN connects the brain B to the pancreas P of the patient.
  • a conduit pancreatic duct PD extends from the pancreas P and discharges into the superior duodenum D.
  • the presence of food contents within the duodenum D may prevent passage of gastric content of the stomach S past the pyloric valve PV into the duodenum D.
  • contents can be forced retrograde past the lower esophageal sphincter LES and into the esophagus E creating the symptoms and discomfort of GERD.
  • the contents discharging from the stomach S into the duodenum D are acidic (and high osmolality) and reside in the duodenum D until pH is elevated (close to a neutral pH of 6-7) and osmolality is normalized.
  • the elevation of pH and reduction of osmolality of chyme in the duodenum D results from exocrine secretion being administered from the pancreas P and from bile from the liver into the duodenum D. This raises the pH and lowers the osmolality of the duodenum D content permitting discharge from the duodenum D and thereby permitting gastric emptying across the pyloric valve PV.
  • gastro-esophageal reflux disease results from a derangement of the feedback loops involved in upper GI digestion and motility control.
  • This problem encompasses receptors and reflexes that regulate the propulsive contractions of the stomach, upper duodenum and biliary tree and the secretions of the exocrine pancreas.
  • the interaction of these receptors and reflexes control gastric emptying (by coordinating gastric propulsive contractions and sphincter [primarily pyloric] tone) and regulate the pH and osmolality of the chyme in the duodenum.
  • ingestate delivered to the stomach is mixed by low intensity gastric mixing contractions with the enzymatic, ionic, including hydrogen ion (H + ), and water secretions of the glands of the stomach.
  • H + hydrogen ion
  • the fluid now called chyme
  • This material is at a very low pH (about 2) and high osmolality, which activates receptors, including those for H + and osmotic pressure, which are abundant in the wall of the ampulla.
  • This receptor activation initiates the series of reflexes that cause pancreatic exocrine secretion to be delivered into the superior duodenum and ampulla.
  • This fluid contains digestive enzymes, water and buffering compounds to raise the pH, and reduce the osmolality, of the chyme.
  • control system If the control system is down regulated by, for example, by increased pH of gastric contents entering the ampulla, feedback may thereby be reduced from the H + receptors in the duodenum that stimulate pancreatic exocrine secretion and bile delivery to the duodenum, then movement of chyme from the superior duodenum is delayed, causing delay of gastric emptying.
  • the drugs used to treat this disease raise pH further dampening the hydrogen-receptor-pancreatic secretion loop, further delaying gastric emptying.
  • Benini “Gastric Emptying and Dyspeptic Symptoms in Patients with Gastroesophageal Reflux”, Amer. J. of Gastroenterology, pp. 1351-1354 (1996).
  • the present invention is directed towards reestablishing the link between gastric emptying and pancreatic secretion delivery, thereby addressing the main pathology of this disease by shortening chyme residence time in the superior duodenum so that intestinal contents move into the distal digestive tract in a more normal manner.
  • this is done by stimulating the H+ ion receptors or by stimulation of the pancreas directly or via its para-sympathetic innervation (pre-ganglionic Vagal nerves). Stimulation of pancreatic exocrine secretion has been shown by direct stimulation of the thoracic vagus nerves in dogs.
  • Acidity can be assessed by measuring bicarbonate. It will be understood that references to ⁇ H includes such indirect measurements. Also, effects of the therapy described herein can be assessed and/or controlled by measuring an indication of pancreatic exocrine secretion or bile (e.g., HCO 3 ⁇ ).
  • An alternative embodiment uses gastrocopic delivery of a paralyzing agent (e.g. botulism toxin) to the pyloric valve along with use of H 2 antagonists or PPI's to manage the acidity of the chyme reaching the duodenum.
  • a paralyzing agent e.g. botulism toxin
  • the gall bladder can be stimulated to encourage bile movement into the duodenum.
  • the gall bladder GB resides below the liver L.
  • the gall bladder is connected to the small intestine (specifically the duodenum D) via a bile duct BD.
  • the bile duct BD can discharge directly into the duodenum D or via the pancreatic duct PD as shown.
  • the bile can normalize the chyme to accelerate duodenal emptying.
  • Bile consists of bile acids (detergents that emulsify lipids), cholesterol, phospholipids, electrolytes such as (Na + , K + , Ca +2 , Cl ⁇ , HCO 3 ⁇ ) and H 2 O. Chapter 4, “The Liver and Biliary Tract”, Gastrointestinal System, 2 nd Ed., M. S. Long editor, Mosby Publisher, London (2002).
  • the gall bladder GB or bile duct can be stimulated indirectly via stimulation of the vagal nerve VN or directly stimulated by an electrode or other stimulator.
  • an electrical stimulator 10 , 20 which may be implanted is provided which alternatively may be directly connected to the Vagal nerve VN (e.g., via stimulation pathway 13 ) or the pancreas P (e.g., via stimulation pathway 11 shown in dashed line) to stimulate the pancreas directly or indirectly to excrete exocrine into the duodenum D (or more distally into the small intestine—e.g., into the jejunum) and increase the pH of chyme in the duodenum D as described.
  • VN Vagal nerve
  • the pancreas P e.g., via stimulation pathway 11 shown in dashed line
  • the same can be done to promote bile release by stimulating the bile duct BD or the gall bladder GB either directly (e.g., via stimulation pathway 11 ) or indirectly (e.g., by stimulating Vagal nerve VN via stimulation pathway 13 ).
  • the duodenum D can be stimulated directly (e.g., via one or more electrodes or other stimulators as indicated by pathway 11 ) to cause propulsive contractions that accelerate duodenum emptying.
  • the frequency may be varied to maximize the response and selectively stimulate exocrine instead of endocrine secretions.
  • the patient may activate the stimulator 10 by remote transmitter to stimulate an electrical charge either after eating (e.g., about 60 to 90 minutes after eating) or on onset of GERD symptoms.
  • an electrical charge either after eating (e.g., about 60 to 90 minutes after eating) or on onset of GERD symptoms.
  • nerve stimulators and organ stimulators available for implantation and are commercially available and which include connectors for connecting directly to nerves.
  • FIG. 2 illustrates an additional embodiment where the patient activated loop is replaced with an automatic loop having a programmable stimulator 20 which receives as an input signals from sensors in the duodenum to measure pH, osmolality or strain (e.g., from baro-sensors) on the duodenum indicating filling or may measure acidity in the esophagus or strain on the lower esophageal sphincter LES or stomach S all of which may be provided to the implantable controller 20 which can be provided with desirable software to process the incoming signals and generate a stimulating signal to either the Vagal nerve, the pancreas P, the gall bladder GB, the bile duct BD or the duodenum D (or jejunum) directly in response to such received signals.
  • a programmable stimulator 20 which receives as an input signals from sensors in the duodenum to measure pH, osmolality or strain (e.g., from baro-sensors) on the duodenum indicating filling or may measure

Abstract

GERD is treated through a method and apparatus of stimulating the body organ to accelerate a discharge of contents from the duodenum of the patient to thereby encourage discharge of contents from the stomach of the patient across the pyloric valve and into the duodenum.

Description

  • This application is a divisional of application Ser. No. 10/358,093, filed Feb. 3, 2003, which application is incorporated herein by reference.
  • I. BACKGROUND OF THE INVENTION
  • 1. Field of the Invention
  • This invention pertains to the field of treatment of gastro-esophageal reflux disease (GERD).
  • 2. Description of the Prior Art
  • Gastro-esophageal reflux is a physical condition in which stomach acids reflux, or flow back from the stomach into the esophagus. Frequent reflux episodes may result in a more severe problem known as gastro-esophageal reflux disease (GERD). GERD is the most common form of dyspepsia, being present in approximately 40% of adults in the United States on an intermittent basis and some 10% on a daily basis as described in U.S. Pat. No. 6,098,629 Johnson et al., dated Aug. 8, 2000.
  • As indicated in Johnson et al., dyspepsia, or heartburn is defined as a burning sensation or discomfort behind the breastbone or sternum and is the most common symptom of GERD. Other symptoms of GERD include dysphasia, odynophagia, hemorrhage, water brash and pulmonary manifestations such as asthma, coughing, or intermittent wheezing due to acid aspiration.
  • GERD is generally considered to be the result of a motility disorder which permits the abnormal and prolonged exposure of the esophageal lumen to acidic gastric contents. Hunt, “The Relationship between the Control of pH and Healing and Symptom Relief in Gastro-Oesophageal Reflux Disease”, Ailment Pharmacol Ther., 9 (Suppl. 1) pp. 3-7 (1995). Many factors are believed to contribute to the onset of GERD. These include transient lower esophageal sphincter (LES) relaxations, decreased LES resting tone, delayed stomach emptying and an ineffective esophageal clearance.
  • Treatments for GERD include lifestyle changes such as weight loss, avoidance of certain foods (e.g., coffee, caffeine, alcohol, chocolate) that exacerbate the symptoms of GERD and avoidance of excessive bending. Elevation of the head of a patient's bed helps prevent nocturnal reflux. While these avoidance strategies may be helpful there is relatively little data pointing to the efficacy of lifestyle modification for the treatment of GERD.
  • Certain medications used for treatment of GERD have been administered for years with varying success. Conventional antacids such as Tums® and Rolaids® may, in some patients, produce short-term relief but often have side effects including diarrhea and constipation.
  • Other drugs have been more effective at controlling GERD but fail to treat underlying causes of the disease and have been proven to be extremely expensive and not readily available to all patients due to such expense. Examples of such drugs are H2-receptor antagonists (which control gastric acid secretion in the basal state) and proton pump inhibitors (which control meal-stimulated acid secretion). Hunt, id. Both classes of drugs can raise intragastric pH to or about 4 for varying durations. Hunt, supra.
  • Surgery treatments are also known for the treatment of GERD and include techniques for bulking the lower esophageal sphincter such as techniques described in U.S. Pat. No. 6,098,629 Johnson et al, Aug. 8, 2000. Other surgical techniques include placement of pacemakers for stimulating muscle contractions in the esophageal sphincter, the stomach muscles or in the pyloric valve. U.S. Pat. No. 6,104,955 to Bourgeois, U.S. Pat. No. 5,861,014 to Familoni.
  • A summary of GERD treatments can be found in DeVault, et al., “Updated Guidelines for the Diagnosis and Treatment of Gastroesophageal Reflux Disease”, Amer. J. of Gastroenterology, Vol. 94, No. 6, pp. 1434-1442 (1999).
  • Notwithstanding multiple attempts at various types of treatment, GERD continues to be a serious disease proving to be difficult to treat by any of the foregoing prior art techniques. In view of the foregoing and notwithstanding various efforts exemplified in the prior art, there remains a need for an effective treatment for GERD. It is an object of the present invention to provide a novel treatment and novel apparatus for the treatment of GERD.
  • II. SUMMARY OF THE INVENTION
  • One inventive aspect of the present disclosure relates to methods and devices for treating GERD by stimulating the duodenum of a patient to accelerate gastric emptying.
  • According to a preferred embodiment of the present invention, a method and apparatus are disclosed for treating gastro-esophageal reflux disease of a patient. The method includes stimulating a body organ to accelerate a discharge of contents from a duodenum of a patient to thereby encourage discharge of contents from a stomach of the patient across a pyloric valve of the patient and into the duodenum. The apparatus of the invention includes a signal generator for generating a stimulation signal. A conductor electrically connects the signal generator to the body organ to accelerate a discharge of contents from the duodenum of the patient to encourage gastric emptying.
  • III. BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a schematic representation of a gastric-emptying feedback loop with a patient-controlled stimulator for stimulating an organ of the loop; and
  • FIG. 2 is a view similar to FIG. 1 with an automatic controller replacing the patient-controller of FIG. 1 and with feedback circuits to the automatic controller schematically represented.
  • IV. DESCRIPTION OF THE PREFERRED EMBODIMENT
  • With reference now to the various drawing figures in which identical elements are numbered identically throughout, a description of the preferred embodiment of the present invention will now be described.
  • With initial reference to FIG. 1, a gastric emptying feedback loop is shown schematically for ease of illustration. The feedback loop illustrates a patient's stomach S which is provided with food from the esophagus E. A lower esophageal sphincter LES is shown positioned between the esophagus E and the stomach S. The lower esophageal sphincter normally provides control of reflux of stomach contents into the esophagus E.
  • On a proximal or lower end of the stomach S the stomach discharges into the superior duodenum D which is an upper portion of the intestines. The superior duodenum D and the stomach S are separated by a pyloric valve PV which opens to permit gastric emptying from the stomach into the duodenum D.
  • Also schematically illustrated in FIG. 1 are nerve paths N providing signal flow paths from both the superior duodenum D and the stomach S to the brain B. An efferent Vagal nerve VN connects the brain B to the pancreas P of the patient. A conduit (pancreatic duct PD) extends from the pancreas P and discharges into the superior duodenum D.
  • The presence of food contents within the duodenum D (such contents being referred to as “chyme”) may prevent passage of gastric content of the stomach S past the pyloric valve PV into the duodenum D. As long as such gastric contents cannot be passed into the duodenum D, such contents can be forced retrograde past the lower esophageal sphincter LES and into the esophagus E creating the symptoms and discomfort of GERD. The contents discharging from the stomach S into the duodenum D are acidic (and high osmolality) and reside in the duodenum D until pH is elevated (close to a neutral pH of 6-7) and osmolality is normalized.
  • The elevation of pH and reduction of osmolality of chyme in the duodenum D results from exocrine secretion being administered from the pancreas P and from bile from the liver into the duodenum D. This raises the pH and lowers the osmolality of the duodenum D content permitting discharge from the duodenum D and thereby permitting gastric emptying across the pyloric valve PV.
  • According to the present invention, gastro-esophageal reflux disease (GERD) results from a derangement of the feedback loops involved in upper GI digestion and motility control. This problem encompasses receptors and reflexes that regulate the propulsive contractions of the stomach, upper duodenum and biliary tree and the secretions of the exocrine pancreas. The interaction of these receptors and reflexes control gastric emptying (by coordinating gastric propulsive contractions and sphincter [primarily pyloric] tone) and regulate the pH and osmolality of the chyme in the duodenum. This chemo-regulation is mediated through control of bile delivery and stimulation of secretion by the exocrine pancreas of fluid delivered to the superior duodenum. Chey et al., “Neural Hormonal Regulation of Exocrine Pancreatic Secretion”, Pancreatology, pp. 320-335 (2001).
  • Normally, ingestate delivered to the stomach is mixed by low intensity gastric mixing contractions with the enzymatic, ionic, including hydrogen ion (H+), and water secretions of the glands of the stomach. When the material is adequately reduced in size and is a smooth consistency, the fluid, now called chyme, is delivered to the ampulla of the small intestine by the much stronger propulsive, or emptying, contractions of the stomach coupled with transitory relaxation of the pyloric sphincter. This material is at a very low pH (about 2) and high osmolality, which activates receptors, including those for H+ and osmotic pressure, which are abundant in the wall of the ampulla. This receptor activation initiates the series of reflexes that cause pancreatic exocrine secretion to be delivered into the superior duodenum and ampulla. This fluid contains digestive enzymes, water and buffering compounds to raise the pH, and reduce the osmolality, of the chyme.
  • Once a neutral pH and physiological osmolality are achieved, then propulsive contractions in the superior duodenum move the chyme out of the superior portion into the length of the duodenum; At which point the stretch and baro-receptors in the ampulla allow the pyloric sphincter to relax and another bolus of gastric contents is delivered into the ampulla by the peristaltic gastric emptying contractions. This material, at a very low pH (less than 2), activates hydrogen ion (H+) on receptors of the ampulla (upper most portion of the duodenum) causing the pancreatic fluids to be delivered to the material in the ampulla restarting the cycle as described above. Chapter 3, “The Stomach”, Gastrointestinal System, 2nd Ed., M. S. Long editor, Mosby Publisher, London (2002).
  • If the control system is down regulated by, for example, by increased pH of gastric contents entering the ampulla, feedback may thereby be reduced from the H+ receptors in the duodenum that stimulate pancreatic exocrine secretion and bile delivery to the duodenum, then movement of chyme from the superior duodenum is delayed, causing delay of gastric emptying. Mabayo, et al., “Inhibition of Food Passage by Osmeprazole in the Chicken”, European J. of Pharmacology, pp. 161-165 (1995).
  • In GERD, this reflex is inhibited in such a way that the stomach empties more slowly so that the gastric emptying contractions force gastric contents to flow retrograde into the esophagus. This is a result of the situation in which the gastric emptying contractions are vigorous but must operate against a contracted pyloric sphincter. These vigorous peristaltic contractions eventually begin to force gastric contents to flow retrograde into the esophagus because of the inherent imbalance between a very strong pyloric sphincter and a much weaker gastro-esophageal sphincter. The delay in gastric emptying is directly related to a slow down in the transport of chyme out of the ampulla and superior duodenum. The drugs used to treat this disease raise pH further dampening the hydrogen-receptor-pancreatic secretion loop, further delaying gastric emptying. Benini, “Gastric Emptying and Dyspeptic Symptoms in Patients with Gastroesophageal Reflux”, Amer. J. of Gastroenterology, pp. 1351-1354 (1996).
  • The present invention is directed towards reestablishing the link between gastric emptying and pancreatic secretion delivery, thereby addressing the main pathology of this disease by shortening chyme residence time in the superior duodenum so that intestinal contents move into the distal digestive tract in a more normal manner. According to a first embodiment, this is done by stimulating the H+ ion receptors or by stimulation of the pancreas directly or via its para-sympathetic innervation (pre-ganglionic Vagal nerves). Stimulation of pancreatic exocrine secretion has been shown by direct stimulation of the thoracic vagus nerves in dogs. Kaminski et al., “The Effect of Electrical Vagal Stimulation on Canine Pancreatic Exocrine Function”, Surgery, pp. 545-552 (1975). This results in a more rapid (normal) neutralization of chyme in the ampulla, allowing it move down the duodenum more quickly so that gastric emptying is returned to a more normal pace.
  • Acidity (pH) can be assessed by measuring bicarbonate. It will be understood that references to −H includes such indirect measurements. Also, effects of the therapy described herein can be assessed and/or controlled by measuring an indication of pancreatic exocrine secretion or bile (e.g., HCO3 ).
  • An alternative embodiment uses gastrocopic delivery of a paralyzing agent (e.g. botulism toxin) to the pyloric valve along with use of H2 antagonists or PPI's to manage the acidity of the chyme reaching the duodenum.
  • As an additional alternative to pancreatic stimulation, the gall bladder can be stimulated to encourage bile movement into the duodenum. Shown schematically in the figures, the gall bladder GB resides below the liver L. The gall bladder is connected to the small intestine (specifically the duodenum D) via a bile duct BD. The bile duct BD can discharge directly into the duodenum D or via the pancreatic duct PD as shown. The bile can normalize the chyme to accelerate duodenal emptying. Bile consists of bile acids (detergents that emulsify lipids), cholesterol, phospholipids, electrolytes such as (Na+, K+, Ca+2, Cl, HCO3 ) and H2O. Chapter 4, “The Liver and Biliary Tract”, Gastrointestinal System, 2nd Ed., M. S. Long editor, Mosby Publisher, London (2002). The gall bladder GB or bile duct can be stimulated indirectly via stimulation of the vagal nerve VN or directly stimulated by an electrode or other stimulator.
  • As illustrated in the figures, an electrical stimulator 10, 20 which may be implanted is provided which alternatively may be directly connected to the Vagal nerve VN (e.g., via stimulation pathway 13) or the pancreas P (e.g., via stimulation pathway 11 shown in dashed line) to stimulate the pancreas directly or indirectly to excrete exocrine into the duodenum D (or more distally into the small intestine—e.g., into the jejunum) and increase the pH of chyme in the duodenum D as described. Alternatively, the same can be done to promote bile release by stimulating the bile duct BD or the gall bladder GB either directly (e.g., via stimulation pathway 11) or indirectly (e.g., by stimulating Vagal nerve VN via stimulation pathway 13). In other embodiments, the duodenum D can be stimulated directly (e.g., via one or more electrodes or other stimulators as indicated by pathway 11) to cause propulsive contractions that accelerate duodenum emptying. The frequency may be varied to maximize the response and selectively stimulate exocrine instead of endocrine secretions. Rösch et al., “Frequency-Dependent Secretion of Pancreatic Amylase, Lipase, Trypsin, and Chymotrypsin During Vagal Stimulation in Rats”, Pancreas, pp. 499-506 (1990). See, also, Berthoud et al., “Characteristics of Gastric and Pancreatic Reponses to Vagal Stimulation with Varied Frequencies: Evidence for Different Fiber Calibers?”, J. Auto. Nervous Sys., pp. 77-84 (1987) (showed frequency-response relationship with insulin, i.e., significantly less insulin was released at lower frequencies—2 Hz v. 8 Hz—also, frequency-response curves evidenced distinctly different profiles for gastric, pancreatic and cardiovascular responses.) Slight insulin release can maximize pancreatic exocrine secretion. Chey et al., “Neural Hormonal Regulation of Exocrine Pancreatic Secretion”, Pancreatology, pp. 320-335 (2001).
  • With a patient control stimulation as shown in FIG. 1, the patient may activate the stimulator 10 by remote transmitter to stimulate an electrical charge either after eating (e.g., about 60 to 90 minutes after eating) or on onset of GERD symptoms. It will be appreciated that there are a wide variety of nerve stimulators and organ stimulators available for implantation and are commercially available and which include connectors for connecting directly to nerves.
  • FIG. 2 illustrates an additional embodiment where the patient activated loop is replaced with an automatic loop having a programmable stimulator 20 which receives as an input signals from sensors in the duodenum to measure pH, osmolality or strain (e.g., from baro-sensors) on the duodenum indicating filling or may measure acidity in the esophagus or strain on the lower esophageal sphincter LES or stomach S all of which may be provided to the implantable controller 20 which can be provided with desirable software to process the incoming signals and generate a stimulating signal to either the Vagal nerve, the pancreas P, the gall bladder GB, the bile duct BD or the duodenum D (or jejunum) directly in response to such received signals. It will be appreciated that stimulators and controllers are well within the skill of the art. U.S. Pat. No. 5,540,730, which is hereby incorporated by reference in its entirety, teaches a neurostimulator to stimulate a vagus nerve to treat a motility disorder. U.S. Pat. No. 5,292,344, which is hereby incorporated by reference in its entirety, teaches gastrointestinal sensors including pH sensors.
  • With the foregoing detailed description of the present invention, it has been shown how the objects of the invention have been attained in a preferred manner. Modifications and equivalents of disclosed concepts such as those which might readily occur to one skilled in the art, are intended to be included in the scope of the claims which are appended hereto.

Claims (20)

1. A method for treating gastro-esophageal reflux disease (GERD) of a patient comprising:
treating a body organ to accelerate a discharge of contents through at least a portion of a small intestine of the patient to thereby encourage discharge of contents from a stomach of the patient across a pyloric valve of the patient and into said small intestine.
2. A method according to claim 1 wherein said portion is a duodenum of said patient.
3. A method according to claim 1 wherein said treating is a stimulation selected to increase a pH of said contents of said portion of said small intestine.
4. A method according to claim 1 wherein said treating is a stimulation selected to decrease an osmolality of said contents of said portion of said small intestine.
5. A method according to claim 1 wherein said organ is a pancreas of said patient and said treating is a stimulation of said organ selected to stimulate delivery of an exocrine secretion from said pancreas to said portion of said small intestine.
6. A method according to claim 5 wherein said pancreas is stimulated directly.
7. A method according to claim 5 wherein said pancreas is indirectly stimulated by stimulating at least a nerve of said pancreas.
8. A method according to claim 5 wherein said stimulation is initiated by said patient.
9. A method according to claim 5 wherein said stimulation is initiated by a controller operatively connected to stimulating electrodes and having an input operatively connected to a sensor.
10. A method according to claim 9 wherein said sensor senses a pH level of said portion of said small intestine.
11. A method according to claim 9 wherein said sensor senses a degree of filling of said portion of said small intestine.
12. A method according to claim 9 wherein said sensor senses a degree of osmolality within said portion of said small intestine.
13. A method according to claim 9 wherein said sensor senses a degree of motility within said portion of said small intestine.
14. A method according to claim 1 wherein said treatment includes delivery of a paralyzing agent to said pyloric valve.
15. A method according to claim 14 wherein said delivery is done in conjunction with agents to manage acidity of a content of said portion of said small intestine.
16. A method according to claim 15 wherein said agents are selected from a group including H2 antagonists and PPI's.
17. A method according to claim 5 wherein said stimulation is an electrical stimulation.
18. A method according to claim 17 wherein said stimulation is at a frequency selected to encourage exocrine secretion without excess endocrine secretion.
19. A method according to claim 1 wherein said treating is a stimulation selected to encourage bile delivery to the portion of said small intestine.
20. A method according to claim 1, wherein the body organ is a duodenum of said patient.
US11/450,202 2003-02-03 2006-06-09 Method and apparatus for treatment of gastro-esophageal reflux disease (GERD) Abandoned US20060229685A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/450,202 US20060229685A1 (en) 2003-02-03 2006-06-09 Method and apparatus for treatment of gastro-esophageal reflux disease (GERD)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/358,093 US20040172084A1 (en) 2003-02-03 2003-02-03 Method and apparatus for treatment of gastro-esophageal reflux disease (GERD)
US11/450,202 US20060229685A1 (en) 2003-02-03 2006-06-09 Method and apparatus for treatment of gastro-esophageal reflux disease (GERD)

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/358,093 Division US20040172084A1 (en) 2003-02-03 2003-02-03 Method and apparatus for treatment of gastro-esophageal reflux disease (GERD)

Publications (1)

Publication Number Publication Date
US20060229685A1 true US20060229685A1 (en) 2006-10-12

Family

ID=32907599

Family Applications (11)

Application Number Title Priority Date Filing Date
US10/358,093 Abandoned US20040172084A1 (en) 2003-02-03 2003-02-03 Method and apparatus for treatment of gastro-esophageal reflux disease (GERD)
US10/675,818 Abandoned US20040176812A1 (en) 2003-02-03 2003-09-29 Enteric rhythm management
US10/674,330 Expired - Fee Related US7489969B2 (en) 2003-02-03 2003-09-29 Vagal down-regulation obesity treatment
US10/674,324 Abandoned US20040172085A1 (en) 2003-02-03 2003-09-29 Nerve stimulation and conduction block therapy
US11/450,202 Abandoned US20060229685A1 (en) 2003-02-03 2006-06-09 Method and apparatus for treatment of gastro-esophageal reflux disease (GERD)
US11/891,770 Expired - Lifetime US7729771B2 (en) 2003-02-03 2007-08-13 Nerve stimulation and blocking for treatment of gastrointestinal disorders
US12/721,603 Expired - Fee Related US8010204B2 (en) 2003-02-03 2010-03-11 Nerve blocking for treatment of gastrointestinal disorders
US13/188,293 Expired - Fee Related US8538542B2 (en) 2003-02-03 2011-07-21 Nerve stimulation and blocking for treatment of gastrointestinal disorders
US14/019,126 Expired - Fee Related US9174040B2 (en) 2003-02-03 2013-09-05 Nerve stimulation and blocking for treatment of gastrointestinal disorders
US14/930,233 Expired - Fee Related US9682233B2 (en) 2003-02-03 2015-11-02 Nerve stimulation and blocking for treatment of gastrointestinal disorders
US15/625,755 Abandoned US20170304615A1 (en) 2003-02-03 2017-06-16 Nerve stimulation and blocking for treatment of gastrointestinal disorders

Family Applications Before (4)

Application Number Title Priority Date Filing Date
US10/358,093 Abandoned US20040172084A1 (en) 2003-02-03 2003-02-03 Method and apparatus for treatment of gastro-esophageal reflux disease (GERD)
US10/675,818 Abandoned US20040176812A1 (en) 2003-02-03 2003-09-29 Enteric rhythm management
US10/674,330 Expired - Fee Related US7489969B2 (en) 2003-02-03 2003-09-29 Vagal down-regulation obesity treatment
US10/674,324 Abandoned US20040172085A1 (en) 2003-02-03 2003-09-29 Nerve stimulation and conduction block therapy

Family Applications After (6)

Application Number Title Priority Date Filing Date
US11/891,770 Expired - Lifetime US7729771B2 (en) 2003-02-03 2007-08-13 Nerve stimulation and blocking for treatment of gastrointestinal disorders
US12/721,603 Expired - Fee Related US8010204B2 (en) 2003-02-03 2010-03-11 Nerve blocking for treatment of gastrointestinal disorders
US13/188,293 Expired - Fee Related US8538542B2 (en) 2003-02-03 2011-07-21 Nerve stimulation and blocking for treatment of gastrointestinal disorders
US14/019,126 Expired - Fee Related US9174040B2 (en) 2003-02-03 2013-09-05 Nerve stimulation and blocking for treatment of gastrointestinal disorders
US14/930,233 Expired - Fee Related US9682233B2 (en) 2003-02-03 2015-11-02 Nerve stimulation and blocking for treatment of gastrointestinal disorders
US15/625,755 Abandoned US20170304615A1 (en) 2003-02-03 2017-06-16 Nerve stimulation and blocking for treatment of gastrointestinal disorders

Country Status (5)

Country Link
US (11) US20040172084A1 (en)
EP (1) EP2366425A1 (en)
AT (2) ATE547148T1 (en)
AU (1) AU2009245845B2 (en)
DK (1) DK1601414T3 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080281365A1 (en) * 2007-05-09 2008-11-13 Tweden Katherine S Neural signal duty cycle
US20090210019A1 (en) * 2008-02-14 2009-08-20 Dennis Dong-Won Kim Treatment of excess weight by neural downregulation in combination with compositions
US20090254143A1 (en) * 2008-04-04 2009-10-08 Tweden Katherine S Methods and systems for glucose regulation
US7672727B2 (en) 2005-08-17 2010-03-02 Enteromedics Inc. Neural electrode treatment
US7693577B2 (en) 2003-02-03 2010-04-06 Enteromedics Inc. Irritable bowel syndrome treatment
US7729771B2 (en) 2003-02-03 2010-06-01 Enteromedics Inc. Nerve stimulation and blocking for treatment of gastrointestinal disorders
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US7844338B2 (en) 2003-02-03 2010-11-30 Enteromedics Inc. High frequency obesity treatment
US8825164B2 (en) 2010-06-11 2014-09-02 Enteromedics Inc. Neural modulation devices and methods
US11413296B2 (en) 2005-11-12 2022-08-16 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract

Families Citing this family (269)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7076307B2 (en) * 2002-05-09 2006-07-11 Boveja Birinder R Method and system for modulating the vagus nerve (10th cranial nerve) with electrical pulses using implanted and external components, to provide therapy neurological and neuropsychiatric disorders
US6587719B1 (en) * 1999-07-01 2003-07-01 Cyberonics, Inc. Treatment of obesity by bilateral vagus nerve stimulation
US20070203531A9 (en) * 1999-12-03 2007-08-30 Medtronic, Inc. Heart rate variability control of gastric electrical stimulator
US20060085046A1 (en) * 2000-01-20 2006-04-20 Ali Rezai Methods of treating medical conditions by transvascular neuromodulation of the autonomic nervous system
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
AU6634501A (en) * 2000-06-30 2002-01-14 Sumitomo Pharma Five-membered-ring compound
US6609025B2 (en) * 2001-01-02 2003-08-19 Cyberonics, Inc. Treatment of obesity by bilateral sub-diaphragmatic nerve stimulation
US7756582B2 (en) 2001-05-01 2010-07-13 Intrapace, Inc. Gastric stimulation anchor and method
US7747322B2 (en) 2001-05-01 2010-06-29 Intrapace, Inc. Digestive organ retention device
US7979127B2 (en) 2001-05-01 2011-07-12 Intrapace, Inc. Digestive organ retention device
US7689284B2 (en) 2001-05-01 2010-03-30 Intrapace, Inc. Pseudounipolar lead for stimulating a digestive organ
US7616996B2 (en) 2005-09-01 2009-11-10 Intrapace, Inc. Randomized stimulation of a gastrointestinal organ
US7702394B2 (en) 2001-05-01 2010-04-20 Intrapace, Inc. Responsive gastric stimulator
US20080077192A1 (en) 2002-05-03 2008-03-27 Afferent Corporation System and method for neuro-stimulation
US7837719B2 (en) 2002-05-09 2010-11-23 Daemen College Electrical stimulation unit and waterbath system
AU2004212004B2 (en) 2003-02-13 2008-01-10 Albert Einstein College Of Medicine Of Yeshiva University Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus
US7684865B2 (en) * 2003-03-14 2010-03-23 Endovx, Inc. Methods and apparatus for treatment of obesity
US20040226556A1 (en) 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
US20050070970A1 (en) * 2003-09-29 2005-03-31 Knudson Mark B. Movement disorder stimulation with neural block
US20050070974A1 (en) * 2003-09-29 2005-03-31 Knudson Mark B. Obesity and eating disorder stimulation treatment with neural block
US7054690B2 (en) 2003-10-22 2006-05-30 Intrapace, Inc. Gastrointestinal stimulation device
US9050469B1 (en) 2003-11-26 2015-06-09 Flint Hills Scientific, Llc Method and system for logging quantitative seizure information and assessing efficacy of therapy using cardiac signals
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
AU2005225458B2 (en) 2004-03-25 2008-12-04 The Feinstein Institutes For Medical Research Neural tourniquet
EP1750799A2 (en) * 2004-05-04 2007-02-14 The Cleveland Clinic Foundation Methods of treating medical conditions by neuromodulation of the sympathetic nervous system
US7803195B2 (en) * 2004-06-03 2010-09-28 Mayo Foundation For Medical Education And Research Obesity treatment and device
US7664551B2 (en) * 2004-07-07 2010-02-16 Medtronic Transneuronix, Inc. Treatment of the autonomic nervous system
US20060020298A1 (en) * 2004-07-20 2006-01-26 Camilleri Michael L Systems and methods for curbing appetite
US20060020277A1 (en) * 2004-07-20 2006-01-26 Gostout Christopher J Gastric reshaping devices and methods
US8452407B2 (en) * 2004-08-16 2013-05-28 Boston Scientific Neuromodulation Corporation Methods for treating gastrointestinal disorders
US20060070334A1 (en) * 2004-09-27 2006-04-06 Blue Hen, Llc Sidewall plank for constructing a trailer and associated trailer sidewall construction
US7833279B2 (en) * 2004-11-12 2010-11-16 Enteromedics Inc. Pancreatic exocrine secretion diversion apparatus and method
AU2005323463B2 (en) 2004-12-27 2009-11-19 The Feinstein Institutes For Medical Research Treating inflammatory disorders by electrical vagus nerve stimulation
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
US8600521B2 (en) 2005-01-27 2013-12-03 Cyberonics, Inc. Implantable medical device having multiple electrode/sensor capability and stimulation based on sensed intrinsic activity
US8565867B2 (en) 2005-01-28 2013-10-22 Cyberonics, Inc. Changeable electrode polarity stimulation by an implantable medical device
US7454245B2 (en) * 2005-01-28 2008-11-18 Cyberonics, Inc. Trained and adaptive response in a neurostimulator
US9314633B2 (en) 2008-01-25 2016-04-19 Cyberonics, Inc. Contingent cardio-protection for epilepsy patients
US7561918B2 (en) * 2005-01-28 2009-07-14 Cyberonics, Inc. Autocapture in a neurostimulator
US8371307B2 (en) 2005-02-08 2013-02-12 Koninklijke Philips Electronics N.V. Methods and devices for the treatment of airway obstruction, sleep apnea and snoring
US8096303B2 (en) 2005-02-08 2012-01-17 Koninklijke Philips Electronics N.V Airway implants and methods and devices for insertion and retrieval
US8700163B2 (en) * 2005-03-04 2014-04-15 Cyberonics, Inc. Cranial nerve stimulation for treatment of substance addiction
US7310557B2 (en) * 2005-04-29 2007-12-18 Maschino Steven E Identification of electrodes for nerve stimulation in the treatment of eating disorders
US7835796B2 (en) * 2005-04-29 2010-11-16 Cyberonics, Inc. Weight loss method and device
US7899540B2 (en) * 2005-04-29 2011-03-01 Cyberonics, Inc. Noninvasively adjustable gastric band
US20070016262A1 (en) * 2005-07-13 2007-01-18 Betastim, Ltd. Gi and pancreatic device for treating obesity and diabetes
WO2007013065A2 (en) 2005-07-25 2007-02-01 Rainbow Medical Ltd. Electrical stimulation of blood vessels
US20070027504A1 (en) * 2005-07-27 2007-02-01 Cyberonics, Inc. Cranial nerve stimulation to treat a hearing disorder
US7840280B2 (en) 2005-07-27 2010-11-23 Cyberonics, Inc. Cranial nerve stimulation to treat a vocal cord disorder
US7706874B2 (en) 2005-07-28 2010-04-27 Cyberonics, Inc. Stimulating cranial nerve to treat disorders associated with the thyroid gland
US8660647B2 (en) 2005-07-28 2014-02-25 Cyberonics, Inc. Stimulating cranial nerve to treat pulmonary disorder
US7856273B2 (en) * 2005-07-28 2010-12-21 Cyberonics, Inc. Autonomic nerve stimulation to treat a gastrointestinal disorder
US20070027484A1 (en) * 2005-07-28 2007-02-01 Cyberonics, Inc. Autonomic nerve stimulation to treat a pancreatic disorder
US7822486B2 (en) 2005-08-17 2010-10-26 Enteromedics Inc. Custom sized neural electrodes
US20070073354A1 (en) 2005-09-26 2007-03-29 Knudson Mark B Neural blocking therapy
US7957796B2 (en) 2005-10-28 2011-06-07 Cyberonics, Inc. Using physiological sensor data with an implantable medical device
US8041428B2 (en) 2006-02-10 2011-10-18 Electrocore Llc Electrical stimulation treatment of hypotension
US8676324B2 (en) 2005-11-10 2014-03-18 ElectroCore, LLC Electrical and magnetic stimulators used to treat migraine/sinus headache, rhinitis, sinusitis, rhinosinusitis, and comorbid disorders
US10537728B2 (en) 2005-11-10 2020-01-21 ElectroCore, LLC Vagal nerve stimulation to avert or treat stroke or transient ischemic attack
US9126050B2 (en) 2009-03-20 2015-09-08 ElectroCore, LLC Non-invasive vagus nerve stimulation devices and methods to treat or avert atrial fibrillation
CN101674862A (en) 2005-11-10 2010-03-17 电子核心公司 Electrical stimulation treatment of bronchial constriction
US11297445B2 (en) 2005-11-10 2022-04-05 Electrocore, Inc. Methods and devices for treating primary headache
US11351363B2 (en) 2005-11-10 2022-06-07 Electrocore, Inc. Nerve stimulation devices and methods for treating cardiac arrhythmias
US8676330B2 (en) 2009-03-20 2014-03-18 ElectroCore, LLC Electrical and magnetic stimulators used to treat migraine/sinus headache and comorbid disorders
US8874227B2 (en) 2009-03-20 2014-10-28 ElectroCore, LLC Devices and methods for non-invasive capacitive electrical stimulation and their use for vagus nerve stimulation on the neck of a patient
US8868177B2 (en) 2009-03-20 2014-10-21 ElectroCore, LLC Non-invasive treatment of neurodegenerative diseases
US9174066B2 (en) 2009-03-20 2015-11-03 ElectroCore, LLC Devices and methods for non-invasive capacitive electrical stimulation and their use for vagus nerve stimulation on the neck of a patient
US10441780B2 (en) 2005-11-10 2019-10-15 Electrocore, Inc. Systems and methods for vagal nerve stimulation
US8812112B2 (en) 2005-11-10 2014-08-19 ElectroCore, LLC Electrical treatment of bronchial constriction
US9037247B2 (en) 2005-11-10 2015-05-19 ElectroCore, LLC Non-invasive treatment of bronchial constriction
US8983628B2 (en) 2009-03-20 2015-03-17 ElectroCore, LLC Non-invasive vagal nerve stimulation to treat disorders
US20110125203A1 (en) 2009-03-20 2011-05-26 ElectroCore, LLC. Magnetic Stimulation Devices and Methods of Therapy
US7657310B2 (en) 2006-01-26 2010-02-02 Cyberonics, Inc. Treatment of reproductive endocrine disorders by vagus nerve stimulation
US7801601B2 (en) 2006-01-27 2010-09-21 Cyberonics, Inc. Controlling neuromodulation using stimulus modalities
EP1984064A4 (en) 2006-02-10 2009-11-11 Electrocore Inc Methods and apparatus for treating anaphylaxis using electrical modulation
WO2007094828A2 (en) 2006-02-10 2007-08-23 Electrocore, Inc. Electrical stimulation treatment of hypotension
US8027718B2 (en) * 2006-03-07 2011-09-27 Mayo Foundation For Medical Education And Research Regional anesthetic
EP2026874B1 (en) 2006-03-29 2015-05-20 Dignity Health Vagus nerve stimulation system
US20080183237A1 (en) * 2006-04-18 2008-07-31 Electrocore, Inc. Methods And Apparatus For Treating Ileus Condition Using Electrical Signals
US20100174340A1 (en) * 2006-04-18 2010-07-08 Electrocore, Inc. Methods and Apparatus for Applying Energy to Patients
US7869885B2 (en) 2006-04-28 2011-01-11 Cyberonics, Inc Threshold optimization for tissue stimulation therapy
US9020597B2 (en) 2008-11-12 2015-04-28 Endostim, Inc. Device and implantation system for electrical stimulation of biological systems
US8160709B2 (en) 2006-05-18 2012-04-17 Endostim, Inc. Use of electrical stimulation of the lower esophageal sphincter to modulate lower esophageal sphincter pressure
US8135478B2 (en) * 2006-07-13 2012-03-13 Rainbow Medical Ltd Peltier unidirectional and selective nerve stimulation
US7761168B2 (en) * 2006-07-13 2010-07-20 Yossi Gross Peltier unidirectional and selective nerve stimulation
US20080071173A1 (en) * 2006-09-18 2008-03-20 Aldrich William N Visualizing Formation of Ablation Lesions
US11577077B2 (en) * 2006-10-09 2023-02-14 Endostim, Inc. Systems and methods for electrical stimulation of biological systems
US20150224310A1 (en) * 2006-10-09 2015-08-13 Endostim, Inc. Device and Implantation System for Electrical Stimulation of Biological Systems
US9724510B2 (en) * 2006-10-09 2017-08-08 Endostim, Inc. System and methods for electrical stimulation of biological systems
US9345879B2 (en) 2006-10-09 2016-05-24 Endostim, Inc. Device and implantation system for electrical stimulation of biological systems
US7738961B2 (en) * 2006-10-09 2010-06-15 Endostim, Inc. Method and apparatus for treatment of the gastrointestinal tract
US8543210B2 (en) * 2008-01-25 2013-09-24 Endostim, Inc. Device and implantation system for electrical stimulation of biological systems
US7869867B2 (en) 2006-10-27 2011-01-11 Cyberonics, Inc. Implantable neurostimulator with refractory stimulation
US8874216B2 (en) * 2006-11-03 2014-10-28 Gep Technology, Inc. Apparatus and methods for minimally invasive obesity treatment
US20100217347A1 (en) * 2006-12-16 2010-08-26 Greatbatch, Inc. Neurostimulation for the treatment of pulmonary disorders
US7706875B2 (en) 2007-01-25 2010-04-27 Cyberonics, Inc. Modulation of drug effects by vagus nerve stimulation
WO2008100974A2 (en) * 2007-02-13 2008-08-21 Sharma Virender K Method and apparatus for electrical stimulation of the pancreatico-biliary system
US8068918B2 (en) 2007-03-09 2011-11-29 Enteromedics Inc. Remote monitoring and control of implantable devices
US8224436B2 (en) * 2007-04-02 2012-07-17 Cardiac Research, Inc. Unidirectional neural stimulation systems, devices and methods
US7962214B2 (en) 2007-04-26 2011-06-14 Cyberonics, Inc. Non-surgical device and methods for trans-esophageal vagus nerve stimulation
US7904175B2 (en) 2007-04-26 2011-03-08 Cyberonics, Inc. Trans-esophageal vagus nerve stimulation
US7869884B2 (en) 2007-04-26 2011-01-11 Cyberonics, Inc. Non-surgical device and methods for trans-esophageal vagus nerve stimulation
US7974701B2 (en) 2007-04-27 2011-07-05 Cyberonics, Inc. Dosing limitation for an implantable medical device
WO2009029614A1 (en) 2007-08-27 2009-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
US8696543B2 (en) 2007-10-11 2014-04-15 Kirk Promotion Ltd. Method for controlling flow of intestinal contents in a patient's intestines
BRPI0817871B8 (en) * 2007-10-11 2021-06-22 Implantica Patent Ltd device for controlling the flow in an organ of the body
US20090149799A1 (en) * 2007-12-05 2009-06-11 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for chemical modulation of neural activity
US8180446B2 (en) 2007-12-05 2012-05-15 The Invention Science Fund I, Llc Method and system for cyclical neural modulation based on activity state
US8160695B2 (en) 2007-12-05 2012-04-17 The Invention Science Fund I, Llc System for chemical modulation of neural activity
US8170660B2 (en) * 2007-12-05 2012-05-01 The Invention Science Fund I, Llc System for thermal modulation of neural activity
US8165668B2 (en) 2007-12-05 2012-04-24 The Invention Science Fund I, Llc Method for magnetic modulation of neural conduction
US8170658B2 (en) 2007-12-05 2012-05-01 The Invention Science Fund I, Llc System for electrical modulation of neural conduction
US20090149797A1 (en) * 2007-12-05 2009-06-11 Searete Llc, A Limited Liability Corporation Of The State Of Delaware System for reversible chemical modulation of neural activity
US8195287B2 (en) 2007-12-05 2012-06-05 The Invention Science Fund I, Llc Method for electrical modulation of neural conduction
US8180447B2 (en) 2007-12-05 2012-05-15 The Invention Science Fund I, Llc Method for reversible chemical modulation of neural activity
US8165669B2 (en) 2007-12-05 2012-04-24 The Invention Science Fund I, Llc System for magnetic modulation of neural conduction
US8571643B2 (en) 2010-09-16 2013-10-29 Flint Hills Scientific, Llc Detecting or validating a detection of a state change from a template of heart rate derivative shape or heart beat wave complex
US8337404B2 (en) 2010-10-01 2012-12-25 Flint Hills Scientific, Llc Detecting, quantifying, and/or classifying seizures using multimodal data
US8382667B2 (en) 2010-10-01 2013-02-26 Flint Hills Scientific, Llc Detecting, quantifying, and/or classifying seizures using multimodal data
US9005106B2 (en) 2008-01-31 2015-04-14 Enopace Biomedical Ltd Intra-aortic electrical counterpulsation
US8538535B2 (en) 2010-08-05 2013-09-17 Rainbow Medical Ltd. Enhancing perfusion by contraction
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
WO2009114008A1 (en) * 2008-03-11 2009-09-17 Sharma Virender K Method and apparatus for treatment of the gastrointestinal tract
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
US9211409B2 (en) 2008-03-31 2015-12-15 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of T-cell activity
US8204603B2 (en) * 2008-04-25 2012-06-19 Cyberonics, Inc. Blocking exogenous action potentials by an implantable medical device
US8473062B2 (en) 2008-05-01 2013-06-25 Autonomic Technologies, Inc. Method and device for the treatment of headache
EP2662046B1 (en) 2008-05-09 2023-03-15 Nuvaira, Inc. Systems and assemblies for treating a bronchial tree
US7890182B2 (en) 2008-05-15 2011-02-15 Boston Scientific Neuromodulation Corporation Current steering for an implantable stimulator device involving fractionalized stimulation pulses
EP2318089A4 (en) 2008-07-11 2011-08-10 Gep Technology Inc Apparatus and methods for minimally invasive obesity treatment
US8768469B2 (en) 2008-08-08 2014-07-01 Enteromedics Inc. Systems for regulation of blood pressure and heart rate
US9079028B2 (en) 2008-10-09 2015-07-14 Virender K. Sharma Method and apparatus for stimulating the vascular system
US10603489B2 (en) 2008-10-09 2020-03-31 Virender K. Sharma Methods and apparatuses for stimulating blood vessels in order to control, treat, and/or prevent a hemorrhage
US8457747B2 (en) 2008-10-20 2013-06-04 Cyberonics, Inc. Neurostimulation with signal duration determined by a cardiac cycle
US8417344B2 (en) 2008-10-24 2013-04-09 Cyberonics, Inc. Dynamic cranial nerve stimulation based on brain state determination from cardiac data
US8255057B2 (en) 2009-01-29 2012-08-28 Nevro Corporation Systems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions
JP5726084B2 (en) * 2008-11-11 2015-05-27 シファメド・ホールディングス・エルエルシー Thin electrode assembly
US9795442B2 (en) 2008-11-11 2017-10-24 Shifamed Holdings, Llc Ablation catheters
WO2010059617A2 (en) 2008-11-18 2010-05-27 Setpoint Medical Corporation Devices and methods for optimizing electrode placement for anti-inflamatory stimulation
US8412336B2 (en) 2008-12-29 2013-04-02 Autonomic Technologies, Inc. Integrated delivery and visualization tool for a neuromodulation system
US9320908B2 (en) 2009-01-15 2016-04-26 Autonomic Technologies, Inc. Approval per use implanted neurostimulator
US8494641B2 (en) 2009-04-22 2013-07-23 Autonomic Technologies, Inc. Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism
US20100191304A1 (en) 2009-01-23 2010-07-29 Scott Timothy L Implantable Medical Device for Providing Chronic Condition Therapy and Acute Condition Therapy Using Vagus Nerve Stimulation
US9370654B2 (en) * 2009-01-27 2016-06-21 Medtronic, Inc. High frequency stimulation to block laryngeal stimulation during vagal nerve stimulation
US10512769B2 (en) 2009-03-20 2019-12-24 Electrocore, Inc. Non-invasive magnetic or electrical nerve stimulation to treat or prevent autism spectrum disorders and other disorders of psychological development
US10232178B2 (en) 2009-03-20 2019-03-19 Electrocore, Inc. Non-invasive magnetic or electrical nerve stimulation to treat or prevent dementia
US9174045B2 (en) 2009-03-20 2015-11-03 ElectroCore, LLC Non-invasive electrical and magnetic nerve stimulators used to treat overactive bladder and urinary incontinence
US10376696B2 (en) 2009-03-20 2019-08-13 Electrocore, Inc. Medical self-treatment using non-invasive vagus nerve stimulation
US9254383B2 (en) 2009-03-20 2016-02-09 ElectroCore, LLC Devices and methods for monitoring non-invasive vagus nerve stimulation
US9403001B2 (en) 2009-03-20 2016-08-02 ElectroCore, LLC Non-invasive magnetic or electrical nerve stimulation to treat gastroparesis, functional dyspepsia, and other functional gastrointestinal disorders
US11229790B2 (en) 2013-01-15 2022-01-25 Electrocore, Inc. Mobile phone for treating a patient with seizures
US9333347B2 (en) 2010-08-19 2016-05-10 ElectroCore, LLC Devices and methods for non-invasive electrical stimulation and their use for vagal nerve stimulation on the neck of a patient
US10252074B2 (en) 2009-03-20 2019-04-09 ElectroCore, LLC Nerve stimulation methods for averting imminent onset or episode of a disease
US9375571B2 (en) 2013-01-15 2016-06-28 ElectroCore, LLC Mobile phone using non-invasive nerve stimulation
US8918178B2 (en) 2009-03-20 2014-12-23 ElectroCore, LLC Non-invasive vagal nerve stimulation to treat disorders
US10286212B2 (en) 2009-03-20 2019-05-14 Electrocore, Inc. Nerve stimulation methods for averting imminent onset or episode of a disease
US10220207B2 (en) 2009-03-20 2019-03-05 Electrocore, Inc. Nerve stimulation methods for averting imminent onset or episode of a disease
US8983629B2 (en) 2009-03-20 2015-03-17 ElectroCore, LLC Non-invasive vagal nerve stimulation to treat disorders
US9248286B2 (en) 2009-03-20 2016-02-02 ElectroCore, LLC Medical self-treatment using non-invasive vagus nerve stimulation
CA2757612A1 (en) 2009-04-03 2010-10-07 Intrapace, Inc. Feedback systems and methods to enhance obstructive and other obesity treatments
US8239028B2 (en) 2009-04-24 2012-08-07 Cyberonics, Inc. Use of cardiac parameters in methods and systems for treating a chronic medical condition
US8827912B2 (en) 2009-04-24 2014-09-09 Cyberonics, Inc. Methods and systems for detecting epileptic events using NNXX, optionally with nonlinear analysis parameters
US8788034B2 (en) 2011-05-09 2014-07-22 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US8414559B2 (en) 2009-05-07 2013-04-09 Rainbow Medical Ltd. Gastroretentive duodenal pill
WO2010144578A2 (en) 2009-06-09 2010-12-16 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
EP2445568B1 (en) * 2009-06-24 2020-09-23 Kalila Medical, Inc. Steerable medical delivery devices
CN102639077B (en) 2009-10-27 2015-05-13 赫莱拉公司 Delivery devices with coolable energy emitting assemblies
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
EP4111995A1 (en) 2009-11-11 2023-01-04 Nuvaira, Inc. Device for treating tissue and controlling stenosis
US11051744B2 (en) 2009-11-17 2021-07-06 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
CN105126248B (en) 2009-12-23 2018-06-12 赛博恩特医疗器械公司 For treating the nerve stimulation apparatus of chronic inflammation and system
US11717681B2 (en) 2010-03-05 2023-08-08 Endostim, Inc. Systems and methods for treating gastroesophageal reflux disease
US8447403B2 (en) 2010-03-05 2013-05-21 Endostim, Inc. Device and implantation system for electrical stimulation of biological systems
CA2793737A1 (en) 2010-03-24 2011-09-29 Shifamed Holdings, Llc Intravascular tissue disruption
US8649871B2 (en) 2010-04-29 2014-02-11 Cyberonics, Inc. Validity test adaptive constraint modification for cardiac data used for detection of state changes
US8562536B2 (en) 2010-04-29 2013-10-22 Flint Hills Scientific, Llc Algorithm for detecting a seizure from cardiac data
US8831732B2 (en) 2010-04-29 2014-09-09 Cyberonics, Inc. Method, apparatus and system for validating and quantifying cardiac beat data quality
US9655677B2 (en) 2010-05-12 2017-05-23 Shifamed Holdings, Llc Ablation catheters including a balloon and electrodes
WO2011143468A2 (en) 2010-05-12 2011-11-17 Shifamed, Llc Low profile electrode assembly
US8679009B2 (en) 2010-06-15 2014-03-25 Flint Hills Scientific, Llc Systems approach to comorbidity assessment
US8641646B2 (en) 2010-07-30 2014-02-04 Cyberonics, Inc. Seizure detection using coordinate data
US11400288B2 (en) 2010-08-19 2022-08-02 Electrocore, Inc Devices and methods for electrical stimulation and their use for vagus nerve stimulation on the neck of a patient
US9358381B2 (en) 2011-03-10 2016-06-07 ElectroCore, LLC Non-invasive vagal nerve stimulation to treat disorders
US20200086108A1 (en) 2010-08-19 2020-03-19 Electrocore, Inc. Vagal nerve stimulation to reduce inflammation associated with an aneurysm
US11191953B2 (en) 2010-08-19 2021-12-07 Electrocore, Inc. Systems and methods for vagal nerve stimulation
US8805519B2 (en) 2010-09-30 2014-08-12 Nevro Corporation Systems and methods for detecting intrathecal penetration
WO2012045030A2 (en) 2010-10-01 2012-04-05 Intrapace, Inc. Feedback systems and methods to enhance obstructive and other obesity treatments, optionally using multiple sensors
US8684921B2 (en) 2010-10-01 2014-04-01 Flint Hills Scientific Llc Detecting, assessing and managing epilepsy using a multi-variate, metric-based classification analysis
US11432760B2 (en) 2011-01-12 2022-09-06 Electrocore, Inc. Devices and methods for remote therapy and patient monitoring
US9504390B2 (en) 2011-03-04 2016-11-29 Globalfoundries Inc. Detecting, assessing and managing a risk of death in epilepsy
US9399134B2 (en) 2011-03-10 2016-07-26 ElectroCore, LLC Non-invasive vagal nerve stimulation to treat disorders
US10173048B2 (en) 2011-03-10 2019-01-08 Electrocore, Inc. Electrical and magnetic stimulators used to treat migraine/sinus headache, rhinitis, sinusitis, rhinosinusitis, and comorbid disorders
US11511109B2 (en) 2011-03-10 2022-11-29 Electrocore, Inc. Non-invasive magnetic or electrical nerve stimulation to treat gastroparesis, functional dyspepsia, and other functional gastrointestinal disorders
US11458297B2 (en) 2011-03-10 2022-10-04 Electrocore, Inc Electrical and magnetic stimulators used to treat migraine/sinus headache, rhinitis, sinusitis, rhinosinusitis, and comorbid disorders
WO2012142539A1 (en) 2011-04-14 2012-10-18 Endostim, Inc. Systems and methods for treating gastroesophageal reflux disease
US8725239B2 (en) 2011-04-25 2014-05-13 Cyberonics, Inc. Identifying seizures using heart rate decrease
US9402550B2 (en) 2011-04-29 2016-08-02 Cybertronics, Inc. Dynamic heart rate threshold for neurological event detection
WO2012151396A2 (en) 2011-05-03 2012-11-08 Shifamed Holdings, Llc Steerable delivery sheaths
US9566426B2 (en) 2011-08-31 2017-02-14 ElectroCore, LLC Systems and methods for vagal nerve stimulation
US9925367B2 (en) 2011-09-02 2018-03-27 Endostim, Inc. Laparoscopic lead implantation method
WO2013033673A1 (en) 2011-09-02 2013-03-07 Endostim, Inc. Endoscopic lead implantation method
US9526637B2 (en) 2011-09-09 2016-12-27 Enopace Biomedical Ltd. Wireless endovascular stent-based electrodes
US9549677B2 (en) 2011-10-14 2017-01-24 Flint Hills Scientific, L.L.C. Seizure detection methods, apparatus, and systems using a wavelet transform maximum modulus algorithm
US10576278B2 (en) 2012-02-21 2020-03-03 Virender K. Sharma System and method for electrical stimulation of anorectal structures to treat urinary dysfunction
US9782583B2 (en) 2012-02-21 2017-10-10 Virender K. Sharma System and method for electrical stimulation of anorectal structures to treat urinary dysfunction
US8706234B2 (en) 2012-02-21 2014-04-22 Virender K. Sharma System and method for electrical stimulation of anorectal structures to treat anal dysfunction
EP2822646B1 (en) 2012-03-09 2023-10-18 Mayo Foundation For Medical Education And Research Modulating afferent signals to treat medical conditions
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
US8961550B2 (en) 2012-04-17 2015-02-24 Indian Wells Medical, Inc. Steerable endoluminal punch
US10448839B2 (en) 2012-04-23 2019-10-22 Livanova Usa, Inc. Methods, systems and apparatuses for detecting increased risk of sudden death
US9456916B2 (en) 2013-03-12 2016-10-04 Medibotics Llc Device for selectively reducing absorption of unhealthy food
AU2013305543A1 (en) 2012-08-23 2015-03-19 Endostim, Inc. Device and implantation system for electrical stimulation of biological systems
EP2934540B1 (en) 2012-12-24 2023-08-02 Neurogastrx, Inc. Methods for treating gi tract disorders
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
US10293160B2 (en) 2013-01-15 2019-05-21 Electrocore, Inc. Mobile phone for treating a patient with dementia
US10220211B2 (en) 2013-01-22 2019-03-05 Livanova Usa, Inc. Methods and systems to diagnose depression
US9174049B2 (en) 2013-01-27 2015-11-03 ElectroCore, LLC Systems and methods for electrical stimulation of sphenopalatine ganglion and other branches of cranial nerves
US9498619B2 (en) 2013-02-26 2016-11-22 Endostim, Inc. Implantable electrical stimulation leads
US9011365B2 (en) 2013-03-12 2015-04-21 Medibotics Llc Adjustable gastrointestinal bifurcation (AGB) for reduced absorption of unhealthy food
US9067070B2 (en) 2013-03-12 2015-06-30 Medibotics Llc Dysgeusia-inducing neurostimulation for modifying consumption of a selected nutrient type
US9370660B2 (en) 2013-03-29 2016-06-21 Rainbow Medical Ltd. Independently-controlled bidirectional nerve stimulation
US10349824B2 (en) 2013-04-08 2019-07-16 Apama Medical, Inc. Tissue mapping and visualization systems
CN110141177B (en) 2013-04-08 2021-11-23 阿帕玛医疗公司 Ablation catheter
US10098694B2 (en) 2013-04-08 2018-10-16 Apama Medical, Inc. Tissue ablation and monitoring thereof
US9427581B2 (en) 2013-04-28 2016-08-30 ElectroCore, LLC Devices and methods for treating medical disorders with evoked potentials and vagus nerve stimulation
WO2015009495A1 (en) 2013-07-17 2015-01-22 Cook Medical Technologies Llc Ablation mesh
CN105848708A (en) 2013-09-03 2016-08-10 恩多斯蒂姆股份有限公司 Methods and systems of electrode polarity switching in electrical stimulation therapy
US9205258B2 (en) 2013-11-04 2015-12-08 ElectroCore, LLC Nerve stimulator system
EP3065673A4 (en) 2013-11-06 2017-07-12 Enopace Biomedical Ltd. Wireless endovascular stent-based electrodes
US10123896B2 (en) 2014-03-06 2018-11-13 Mayo Foundation For Medical Education And Research Apparatus and methods of inducing weight loss using blood flow control
EP3145582B1 (en) 2014-05-20 2020-10-21 Nevro Corporation Implanted pulse generators with reduced power consumption via signal strength/duration characteristics, and associated systems
WO2015200369A1 (en) 2014-06-24 2015-12-30 Neurogastrx, Inc. Prodrugs of metopimazine
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
WO2016081468A2 (en) 2014-11-17 2016-05-26 Endostim, Inc. Implantable electro-medical device programmable for improved operational life
WO2016126807A1 (en) 2015-02-03 2016-08-11 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US10376145B2 (en) 2015-02-24 2019-08-13 Elira, Inc. Systems and methods for enabling a patient to achieve a weight loss objective using an electrical dermal patch
WO2016138176A1 (en) 2015-02-24 2016-09-01 Elira Therapeutics Llc Systems and methods for enabling appetite modulation and/or improving dietary compliance using an electro-dermal patch
US10335302B2 (en) 2015-02-24 2019-07-02 Elira, Inc. Systems and methods for using transcutaneous electrical stimulation to enable dietary interventions
US10765863B2 (en) 2015-02-24 2020-09-08 Elira, Inc. Systems and methods for using a transcutaneous electrical stimulation device to deliver titrated therapy
US10864367B2 (en) 2015-02-24 2020-12-15 Elira, Inc. Methods for using an electrical dermal patch in a manner that reduces adverse patient reactions
US9956393B2 (en) 2015-02-24 2018-05-01 Elira, Inc. Systems for increasing a delay in the gastric emptying time for a patient using a transcutaneous electro-dermal patch
WO2016160694A1 (en) 2015-03-27 2016-10-06 Shifamed Holdings, Llc Steerable medical devices, systems, and methods of use
EP3285849A4 (en) 2015-04-24 2018-12-26 Shifamed Holdings, LLC Steerable medical devices, systems, and methods of use
US11318310B1 (en) 2015-10-26 2022-05-03 Nevro Corp. Neuromodulation for altering autonomic functions, and associated systems and methods
US10105540B2 (en) 2015-11-09 2018-10-23 Bluewind Medical Ltd. Optimization of application of current
WO2017083257A1 (en) 2015-11-09 2017-05-18 Shifamed Holdings, Llc Steering assemblies for medical devices, and methods of use
WO2017087549A1 (en) 2015-11-16 2017-05-26 Apama Medical, Inc. Energy delivery devices
US10300277B1 (en) 2015-12-14 2019-05-28 Nevro Corp. Variable amplitude signals for neurological therapy, and associated systems and methods
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
US10314501B2 (en) 2016-01-20 2019-06-11 Setpoint Medical Corporation Implantable microstimulators and inductive charging systems
WO2017127756A1 (en) 2016-01-20 2017-07-27 Setpoint Medical Corporation Control of vagal stimulation
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
WO2018094207A1 (en) 2016-11-17 2018-05-24 Endostim, Inc. Modular stimulation system for the treatment of gastrointestinal disorders
US10980999B2 (en) 2017-03-09 2021-04-20 Nevro Corp. Paddle leads and delivery tools, and associated systems and methods
US11173307B2 (en) 2017-08-14 2021-11-16 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
KR102495358B1 (en) 2017-09-25 2023-02-02 삼성전자주식회사 Neuromimetic stimulating apparatus and method thereof
EP3737459A4 (en) 2018-01-30 2021-10-20 Nevro Corp. Efficient use of an implantable pulse generator battery, and associated systems and methods
EP3758793A4 (en) 2018-03-29 2021-12-08 Nevro Corp. Leads having sidewall openings, and associated systems and methods
CA3096702A1 (en) * 2018-04-12 2019-10-17 Reshape Lifesciences, Inc. Simultaneous multi-site vagus nerve neuromodulation for improved glycemic control system and methods
US11413465B2 (en) 2018-04-13 2022-08-16 The Penn State Research Foundation Free-floating millimeter-sized distributed implantable gastric seeds
US11058875B1 (en) 2018-09-19 2021-07-13 Nevro Corp. Motor function in spinal cord injury patients via electrical stimulation, and associated systems and methods
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
US11590352B2 (en) 2019-01-29 2023-02-28 Nevro Corp. Ramped therapeutic signals for modulating inhibitory interneurons, and associated systems and methods
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine
US11400299B1 (en) 2021-09-14 2022-08-02 Rainbow Medical Ltd. Flexible antenna for stimulator

Citations (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3128760A (en) * 1961-08-21 1964-04-14 Winston Electronics Ltd Vagotomy test apparatus
US4114625A (en) * 1976-12-02 1978-09-19 Onat Mustafa V Anti-vomiting, anti-aspirating oral-nasal gastric tube
US4198963A (en) * 1978-10-19 1980-04-22 Michigan Instruments, Inc. Cardiopulmonary resuscitator, defibrillator and monitor
US4867164A (en) * 1983-09-14 1989-09-19 Jacob Zabara Neurocybernetic prosthesis
US5025807A (en) * 1983-09-14 1991-06-25 Jacob Zabara Neurocybernetic prosthesis
US5188104A (en) * 1991-02-01 1993-02-23 Cyberonics, Inc. Treatment of eating disorders by nerve stimulation
US5199430A (en) * 1991-03-11 1993-04-06 Case Western Reserve University Micturitional assist device
US5215086A (en) * 1991-05-03 1993-06-01 Cyberonics, Inc. Therapeutic treatment of migraine symptoms by stimulation
US5226429A (en) * 1991-06-20 1993-07-13 Inamed Development Co. Laparoscopic gastric band and method
US5226426A (en) * 1990-12-18 1993-07-13 Inbae Yoon Safety penetrating instrument
US5231988A (en) * 1991-08-09 1993-08-03 Cyberonics, Inc. Treatment of endocrine disorders by nerve stimulation
US5236480A (en) * 1989-01-05 1993-08-17 Camfil Ab Air filter for workstations and methods of making and using such air filter
US5292344A (en) * 1992-07-10 1994-03-08 Douglas Donald D Percutaneously placed electrical gastrointestinal pacemaker stimulatory system, sensing system, and pH monitoring system, with optional delivery port
US5299569A (en) * 1991-05-03 1994-04-05 Cyberonics, Inc. Treatment of neuropsychiatric disorders by nerve stimulation
US5330515A (en) * 1992-06-17 1994-07-19 Cyberonics, Inc. Treatment of pain by vagal afferent stimulation
US5335657A (en) * 1991-05-03 1994-08-09 Cyberonics, Inc. Therapeutic treatment of sleep disorder by nerve stimulation
US5344438A (en) * 1993-04-16 1994-09-06 Medtronic, Inc. Cuff electrode
US5423872A (en) * 1992-05-29 1995-06-13 Cigaina; Valerio Process and device for treating obesity and syndromes related to motor disorders of the stomach of a patient
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US5514175A (en) * 1994-11-09 1996-05-07 Cerebral Stimulation, Inc. Auricular electrical stimulator
US5540730A (en) * 1995-06-06 1996-07-30 Cyberonics, Inc. Treatment of motility disorders by nerve stimulation
US5601604A (en) * 1993-05-27 1997-02-11 Inamed Development Co. Universal gastric band
US5620955A (en) * 1993-06-18 1997-04-15 Peptide Technologies Corporation Bombesin receptor antagonists and uses thereof
US5716385A (en) * 1996-11-12 1998-02-10 University Of Virginia Crural diaphragm pacemaker and method for treating esophageal reflux disease
US5747060A (en) * 1996-03-26 1998-05-05 Euro-Celtique, S.A. Prolonged local anesthesia with colchicine
US5861014A (en) * 1997-04-30 1999-01-19 Medtronic, Inc. Method and apparatus for sensing a stimulating gastrointestinal tract on-demand
US5919216A (en) * 1997-06-16 1999-07-06 Medtronic, Inc. System and method for enhancement of glucose production by stimulation of pancreatic beta cells
US6091992A (en) * 1997-12-15 2000-07-18 Medtronic, Inc. Method and apparatus for electrical stimulation of the gastrointestinal tract
US6093167A (en) * 1997-06-16 2000-07-25 Medtronic, Inc. System for pancreatic stimulation and glucose measurement
US6097984A (en) * 1998-11-25 2000-08-01 Medtronic, Inc. System and method of stimulation for treating gastro-esophageal reflux disease
US6098629A (en) * 1999-04-07 2000-08-08 Endonetics, Inc. Submucosal esophageal bulking device
US6104955A (en) * 1997-12-15 2000-08-15 Medtronic, Inc. Method and apparatus for electrical stimulation of the gastrointestinal tract
US6111715A (en) * 1997-01-13 2000-08-29 Hitachi, Ltd. Storage apparatus using a magnetoresistive head that employs a sense current selected from plural predetermined sense currents
US6216039B1 (en) * 1997-05-02 2001-04-10 Medtronic Inc. Method and apparatus for treating irregular gastric rhythms
US6238423B1 (en) * 1997-01-13 2001-05-29 Medtronic, Inc. Apparatus and method for treating chronic constipation
US6243607B1 (en) * 1996-09-05 2001-06-05 University Technologies International Inc. Gastro-intestinal electrical pacemaker
US6261280B1 (en) * 1999-03-22 2001-07-17 Medtronic, Inc Method of obtaining a measure of blood glucose
US6292703B1 (en) * 1998-10-08 2001-09-18 Biotronik Mess-Und Therapiegerate Gmbh & Co. Neural electrode arrangement
US6290961B1 (en) * 1993-12-28 2001-09-18 Allergan, Inc. Method for treating dystonia with botulinum toxin type B
US6341236B1 (en) * 1999-04-30 2002-01-22 Ivan Osorio Vagal nerve stimulation techniques for treatment of epileptic seizures
US20020012828A1 (en) * 1998-09-07 2002-01-31 Bojidara Grigorova Fuel cell and gold-containing catalyst for use therein
US20020032468A1 (en) * 1996-04-30 2002-03-14 Hill Michael R.S. Method and system for endotracheal/esophageal stimulation prior to and during a medical procedure
US6364899B1 (en) * 1998-01-23 2002-04-02 Innercool Therapies, Inc. Heat pipe nerve cooler
US6369079B1 (en) * 1998-06-15 2002-04-09 Sepracor, Inc. Methods for treating irritable bowel syndrome using optically pure (+) norcisapride
US20020052336A1 (en) * 1999-02-26 2002-05-02 Yerxa Benjamin R. Method of treating gastrointestinal tract disease with purinergic receptor agonists
US20020055779A1 (en) * 1996-03-05 2002-05-09 Brian J. Andrews Neural prosthesis
US20020072780A1 (en) * 2000-09-26 2002-06-13 Transneuronix, Inc. Method and apparatus for intentional impairment of gastric motility and /or efficiency by triggered electrical stimulation of the gastrointestinal tract with respect to the intrinsic gastric electrical activity
US6405732B1 (en) * 1994-06-24 2002-06-18 Curon Medical, Inc. Method to treat gastric reflux via the detection and ablation of gastro-esophageal nerves and receptors
US20020087192A1 (en) * 2001-01-02 2002-07-04 Barrett Burke T. Treatment of obesity by sub-diaphragmatic nerve stimulation
US20020094962A1 (en) * 2000-12-01 2002-07-18 Gary Ashley Motilide compounds
US20020103424A1 (en) * 2001-01-31 2002-08-01 Swoyer John M. Implantable medical device affixed internally within the gastrointestinal tract
US20030014086A1 (en) * 2001-07-14 2003-01-16 Sharma Virender K. Method and apparatus for electrical stimulation of the lower esophageal sphincter
US20030018367A1 (en) * 2001-07-23 2003-01-23 Dilorenzo Daniel John Method and apparatus for neuromodulation and phsyiologic modulation for the treatment of metabolic and neuropsychiatric disease
US20030040785A1 (en) * 2001-08-21 2003-02-27 Maschino Steve E. Circumneural electrode assembly
US20030045909A1 (en) * 2001-08-31 2003-03-06 Biocontrol Medical Ltd. Selective nerve fiber stimulation for treating heart conditions
US20030045914A1 (en) * 2001-08-31 2003-03-06 Biocontrol Medical Ltd. Treatment of disorders by unidirectional nerve stimulation
US6532388B1 (en) * 1996-04-30 2003-03-11 Medtronic, Inc. Method and system for endotracheal/esophageal stimulation prior to and during a medical procedure
US20030074039A1 (en) * 1999-06-25 2003-04-17 Puskas John D. Devices and methods for vagus nerve stimulation
US6558708B1 (en) * 1995-05-17 2003-05-06 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
US6571127B1 (en) * 1997-07-16 2003-05-27 Impulse Dynamics N.V. Method of increasing the motility of a GI tract
US6587719B1 (en) * 1999-07-01 2003-07-01 Cyberonics, Inc. Treatment of obesity by bilateral vagus nerve stimulation
US6591137B1 (en) * 2000-11-09 2003-07-08 Neuropace, Inc. Implantable neuromuscular stimulator for the treatment of gastrointestinal disorders
US20030144709A1 (en) * 2002-01-25 2003-07-31 Cyberonics, Inc. Nerve stimulation as a treatment for pain
US6610713B2 (en) * 2000-05-23 2003-08-26 North Shore - Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US6611715B1 (en) * 1998-10-26 2003-08-26 Birinder R. Boveja Apparatus and method for neuromodulation therapy for obesity and compulsive eating disorders using an implantable lead-receiver and an external stimulator
US20040039425A1 (en) * 2002-05-29 2004-02-26 Beverley Greenwood-Van Meerveld Spinal cord stimulation as treatment for functional bowel disorders
US20040059383A1 (en) * 1997-08-26 2004-03-25 Puskas John D. Methods of indirectly stimulating the vagus nerve with an electrical field
US20040086531A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc. Methods for treating ulcers and gastroesophageal reflux disease
US20040089313A1 (en) * 1998-02-19 2004-05-13 Curon Medical, Inc. Systems and methods for treating obesity and other gastrointestinal conditions
US6746474B2 (en) * 2002-05-31 2004-06-08 Vahid Saadat Apparatus and methods for cooling a region within the body
US20040127953A1 (en) * 2001-02-20 2004-07-01 Kilgore Kevin L. Systems and methods for reversibly blocking nerve activity
US20040167583A1 (en) * 2003-02-03 2004-08-26 Enteromedics, Inc. Electrode band apparatus and method
US6853862B1 (en) * 1999-12-03 2005-02-08 Medtronic, Inc. Gastroelectric stimulation for influencing pancreatic secretions
US20050038484A1 (en) * 2003-02-03 2005-02-17 Enteromedics, Inc. Controlled vagal blockage therapy
US20050049655A1 (en) * 2003-08-27 2005-03-03 Boveja Birinder R. System and method for providing electrical pulses to the vagus nerve(s) to provide therapy for obesity, eating disorders, neurological and neuropsychiatric disorders with a stimulator, comprising bi-directional communication and network capabilities
US20050070970A1 (en) * 2003-09-29 2005-03-31 Knudson Mark B. Movement disorder stimulation with neural block
US20050070974A1 (en) * 2003-09-29 2005-03-31 Knudson Mark B. Obesity and eating disorder stimulation treatment with neural block
US20050075693A1 (en) * 2003-10-02 2005-04-07 Medtronic, Inc. Driver circuitry switchable between energy transfer and telemetry for an implantable medical device
US6895278B1 (en) * 1999-04-14 2005-05-17 Transneuronix, Inc. Gastric stimulator apparatus and method for use
US20050131485A1 (en) * 2003-02-03 2005-06-16 Enteromedics, Inc. High frequency vagal blockage therapy
US20050137644A1 (en) * 1998-10-26 2005-06-23 Boveja Birinder R. Method and system for vagal blocking and/or vagal stimulation to provide therapy for obesity and other gastrointestinal disorders
US20050143787A1 (en) * 2002-05-09 2005-06-30 Boveja Birinder R. Method and system for providing electrical pulses for neuromodulation of vagus nerve(s), using rechargeable implanted pulse generator
US20050143378A1 (en) * 2003-12-29 2005-06-30 Yun Anthony J. Treatment of conditions through pharmacological modulation of the autonomic nervous system
US20050149141A1 (en) * 2004-01-07 2005-07-07 Starkebaum Warren L. Gastric stimulation for altered perception to treat obesity
US20050149148A1 (en) * 2001-05-17 2005-07-07 Medtronic, Inc. Apparatus and method for blocking activation of tissue or conduction of action potentials while other tissue is being therapeutically activated
US20060015151A1 (en) * 2003-03-14 2006-01-19 Aldrich William N Method of using endoscopic truncal vagoscopy with gastric bypass, gastric banding and other procedures
US6993391B2 (en) * 2000-12-11 2006-01-31 Metacure N.V. Acute and chronic electrical signal therapy for obesity
US20060036293A1 (en) * 2004-08-16 2006-02-16 Whitehurst Todd K Methods for treating gastrointestinal disorders
US7054690B2 (en) * 2003-10-22 2006-05-30 Intrapace, Inc. Gastrointestinal stimulation device
US20070043400A1 (en) * 2005-08-17 2007-02-22 Donders Adrianus P Neural electrode treatment

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3411507A (en) 1964-04-01 1968-11-19 Medtronic Inc Method of gastrointestinal stimulation with electrical pulses
US4441210A (en) 1981-09-18 1984-04-03 Hochmair Erwin S Transcutaneous signal transmission system and methods
US5370675A (en) 1992-08-12 1994-12-06 Vidamed, Inc. Medical probe device and method
CA1215128A (en) 1982-12-08 1986-12-09 Pedro Molina-Negro Electric nerve stimulator device
US4702254A (en) * 1983-09-14 1987-10-27 Jacob Zabara Neurocybernetic prosthesis
AT385894B (en) * 1985-10-04 1988-05-25 Basem Dr Nashef TUBULAR PROBE
US5263480A (en) * 1991-02-01 1993-11-23 Cyberonics, Inc. Treatment of eating disorders by nerve stimulation
US5269303A (en) * 1991-02-22 1993-12-14 Cyberonics, Inc. Treatment of dementia by nerve stimulation
US5571150A (en) * 1994-12-19 1996-11-05 Cyberonics, Inc. Treatment of patients in coma by nerve stimulation
US5591217A (en) * 1995-01-04 1997-01-07 Plexus, Inc. Implantable stimulator with replenishable, high value capacitive power source and method therefor
US5707400A (en) * 1995-09-19 1998-01-13 Cyberonics, Inc. Treating refractory hypertension by nerve stimulation
US5690691A (en) * 1996-05-08 1997-11-25 The Center For Innovative Technology Gastro-intestinal pacemaker having phased multi-point stimulation
US5749907A (en) 1997-02-18 1998-05-12 Pacesetter, Inc. System and method for identifying and displaying medical data which violate programmable alarm conditions
US5830434A (en) 1997-02-26 1998-11-03 Medical University Of South Carolina Foundation For Research Development Methods of treating non-insulin dependent diabetes mellitus with pancreatic polypeptide
JP2001513679A (en) 1997-02-26 2001-09-04 アルフレッド イー マン ファウンデーション フォア サイエンティフィック リサーチ Battery powered patient subcutaneous insertion device
US5938596A (en) 1997-03-17 1999-08-17 Medtronic, Inc. Medical electrical lead
US5836994A (en) * 1997-04-30 1998-11-17 Medtronic, Inc. Method and apparatus for electrical stimulation of the gastrointestinal tract
IT1293974B1 (en) 1997-08-13 1999-03-15 Sorin Biomedica Cardio Spa ACTIVE IMPLANTABLE DEVICE.
US5967977A (en) * 1997-10-03 1999-10-19 Medtronic, Inc. Transesophageal medical lead
US6148222A (en) 1998-07-10 2000-11-14 Cardiocommand, Inc. Esophageal catheters and method of use
US6564102B1 (en) 1998-10-26 2003-05-13 Birinder R. Boveja Apparatus and method for adjunct (add-on) treatment of coma and traumatic brain injury with neuromodulation using an external stimulator
US6366814B1 (en) 1998-10-26 2002-04-02 Birinder R. Boveja External stimulator for adjunct (add-on) treatment for neurological, neuropsychiatric, and urological disorders
US6208902B1 (en) 1998-10-26 2001-03-27 Birinder Bob Boveja Apparatus and method for adjunct (add-on) therapy for pain syndromes utilizing an implantable lead and an external stimulator
US20030212440A1 (en) 2002-05-09 2003-11-13 Boveja Birinder R. Method and system for modulating the vagus nerve (10th cranial nerve) using modulated electrical pulses with an inductively coupled stimulation system
US6505074B2 (en) 1998-10-26 2003-01-07 Birinder R. Boveja Method and apparatus for electrical stimulation adjunct (add-on) treatment of urinary incontinence and urological disorders using an external stimulator
US6615081B1 (en) 1998-10-26 2003-09-02 Birinder R. Boveja Apparatus and method for adjunct (add-on) treatment of diabetes by neuromodulation with an external stimulator
US6678560B1 (en) 1999-01-21 2004-01-13 Cardiac Pacemakers, Inc. Cardiac rhythm management system with electrosurgery mode
US7149773B2 (en) 1999-07-07 2006-12-12 Medtronic, Inc. System and method of automated invoicing for communications between an implantable medical device and a remote computer system or health care provider
US6308105B1 (en) 1999-07-15 2001-10-23 Medtronic Inc. Medical electrical stimulation system using an electrode assembly having opposing semi-circular arms
US6381496B1 (en) 1999-10-01 2002-04-30 Advanced Bionics Corporation Parameter context switching for an implanted device
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6473644B1 (en) * 1999-10-13 2002-10-29 Cyberonics, Inc. Method to enhance cardiac capillary growth in heart failure patients
IT1315260B1 (en) * 1999-12-07 2003-02-03 Valerio Cigaina REMOVABLE GASTRIC BANDAGE
US6418346B1 (en) 1999-12-14 2002-07-09 Medtronic, Inc. Apparatus and method for remote therapy and diagnosis in medical devices via interface systems
SE9904626D0 (en) 1999-12-16 1999-12-16 Pacesetter Ab Programming system for medical devices
US6261572B1 (en) * 2000-01-11 2001-07-17 Allergan Sales, Inc. Method for treating a pancreatic disorder with a neurotoxin
US6612983B1 (en) * 2000-03-28 2003-09-02 Medtronic, Inc. Pancreatic secretion response to stimulation test protocol
US6826428B1 (en) * 2000-04-11 2004-11-30 The Board Of Regents Of The University Of Texas System Gastrointestinal electrical stimulation
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
JP2001356159A (en) * 2000-06-15 2001-12-26 Seiko Epson Corp Gps receiving system
US6505077B1 (en) 2000-06-19 2003-01-07 Medtronic, Inc. Implantable medical device with external recharging coil electrical connection
US7623926B2 (en) 2000-09-27 2009-11-24 Cvrx, Inc. Stimulus regimens for cardiovascular reflex control
US6832114B1 (en) 2000-11-21 2004-12-14 Advanced Bionics Corporation Systems and methods for modulation of pancreatic endocrine secretion and treatment of diabetes
US6761715B2 (en) * 2001-04-26 2004-07-13 Ronald J. Carroll Method and device for neurocryo analgesia and anesthesia
AU2002305357A1 (en) 2001-05-01 2002-11-11 Second Sight, Llc High-density array of micro-machined electrodes for neural stimulation
US7702394B2 (en) 2001-05-01 2010-04-20 Intrapace, Inc. Responsive gastric stimulator
US20060116736A1 (en) 2001-07-23 2006-06-01 Dilorenzo Daniel J Method, apparatus, and surgical technique for autonomic neuromodulation for the treatment of obesity
US6622038B2 (en) * 2001-07-28 2003-09-16 Cyberonics, Inc. Treatment of movement disorders by near-diaphragmatic nerve stimulation
US20040036377A1 (en) 2001-08-15 2004-02-26 Steven Mezinis High voltage lc electric and magnetic field motivator
US6760626B1 (en) 2001-08-29 2004-07-06 Birinder R. Boveja Apparatus and method for treatment of neurological and neuropsychiatric disorders using programmerless implantable pulse generator system
US7974693B2 (en) * 2001-08-31 2011-07-05 Bio Control Medical (B.C.M.) Ltd. Techniques for applying, configuring, and coordinating nerve fiber stimulation
US7734355B2 (en) * 2001-08-31 2010-06-08 Bio Control Medical (B.C.M.) Ltd. Treatment of disorders by unidirectional nerve stimulation
US7187978B2 (en) 2001-11-01 2007-03-06 Medtronic, Inc. Method and apparatus for programming an implantable medical device
US7050856B2 (en) 2002-01-11 2006-05-23 Medtronic, Inc. Variation of neural-stimulation parameters
US6985773B2 (en) * 2002-02-07 2006-01-10 Cardiac Pacemakers, Inc. Methods and apparatuses for implantable medical device telemetry power management
US7689277B2 (en) 2002-03-22 2010-03-30 Leptos Biomedical, Inc. Neural stimulation for treatment of metabolic syndrome and type 2 diabetes
US7689276B2 (en) 2002-09-13 2010-03-30 Leptos Biomedical, Inc. Dynamic nerve stimulation for treatment of disorders
US7236822B2 (en) * 2002-03-22 2007-06-26 Leptos Biomedical, Inc. Wireless electric modulation of sympathetic nervous system
US7239912B2 (en) * 2002-03-22 2007-07-03 Leptos Biomedical, Inc. Electric modulation of sympathetic nervous system
US8145316B2 (en) * 2002-04-08 2012-03-27 Ardian, Inc. Methods and apparatus for renal neuromodulation
US7191012B2 (en) 2003-05-11 2007-03-13 Boveja Birinder R Method and system for providing pulsed electrical stimulation to a craniel nerve of a patient to provide therapy for neurological and neuropsychiatric disorders
US20040193229A1 (en) 2002-05-17 2004-09-30 Medtronic, Inc. Gastric electrical stimulation for treatment of gastro-esophageal reflux disease
US7292890B2 (en) * 2002-06-20 2007-11-06 Advanced Bionics Corporation Vagus nerve stimulation via unidirectional propagation of action potentials
WO2004036377A2 (en) 2002-10-15 2004-04-29 Medtronic Inc. Configuring and testing treatment therapy parameters for a medical device system
US6736722B1 (en) 2002-12-04 2004-05-18 Deere & Company Unloader tube cleaning system for harvesting apparatus
WO2004064918A1 (en) 2003-01-14 2004-08-05 Department Of Veterans Affairs, Office Of General Counsel Cervical wagal stimulation induced weight loss
US20040172084A1 (en) * 2003-02-03 2004-09-02 Knudson Mark B. Method and apparatus for treatment of gastro-esophageal reflux disease (GERD)
US7430449B2 (en) 2003-03-14 2008-09-30 Endovx, Inc. Methods and apparatus for testing disruption of a vagal nerve
US7684865B2 (en) * 2003-03-14 2010-03-23 Endovx, Inc. Methods and apparatus for treatment of obesity
US7783358B2 (en) * 2003-03-14 2010-08-24 Endovx, Inc. Methods and apparatus for treatment of obesity with an ultrasound device movable in two or three axes
DE10318071A1 (en) 2003-04-17 2004-11-25 Forschungszentrum Jülich GmbH Device for desynchronizing neuronal brain activity
US7444184B2 (en) * 2003-05-11 2008-10-28 Neuro And Cardial Technologies, Llc Method and system for providing therapy for bulimia/eating disorders by providing electrical pulses to vagus nerve(s)
US7620454B2 (en) * 2003-05-19 2009-11-17 Medtronic, Inc. Gastro-electric stimulation for reducing the acidity of gastric secretions or reducing the amounts thereof
US7742818B2 (en) * 2003-05-19 2010-06-22 Medtronic, Inc. Gastro-electric stimulation for increasing the acidity of gastric secretions or increasing the amounts thereof
US7149574B2 (en) 2003-06-09 2006-12-12 Palo Alto Investors Treatment of conditions through electrical modulation of the autonomic nervous system
US7797058B2 (en) 2004-08-04 2010-09-14 Ndi Medical, Llc Devices, systems, and methods employing a molded nerve cuff electrode
US7991479B2 (en) * 2003-10-02 2011-08-02 Medtronic, Inc. Neurostimulator programmer with clothing attachable antenna
US7715913B1 (en) * 2004-02-10 2010-05-11 Koninklijke Philips Electronics, N.V. External defibrillator with training mode and method of use
US7486993B2 (en) * 2004-08-05 2009-02-03 Neurotone Systems, Inc. Brain stimulation method and device
US8214047B2 (en) 2004-09-27 2012-07-03 Advanced Neuromodulation Systems, Inc. Method of using spinal cord stimulation to treat gastrointestinal and/or eating disorders or conditions
US7613520B2 (en) 2004-10-21 2009-11-03 Advanced Neuromodulation Systems, Inc. Spinal cord stimulation to treat auditory dysfunction
US8260426B2 (en) 2008-01-25 2012-09-04 Cyberonics, Inc. Method, apparatus and system for bipolar charge utilization during stimulation by an implantable medical device
WO2006087712A2 (en) 2005-02-17 2006-08-24 Metacure N.V. Charger with data transfer capabilities
US7774069B2 (en) * 2005-04-29 2010-08-10 Medtronic, Inc. Alignment indication for transcutaneous energy transfer
US7561923B2 (en) 2005-05-09 2009-07-14 Cardiac Pacemakers, Inc. Method and apparatus for controlling autonomic balance using neural stimulation
US20070016262A1 (en) 2005-07-13 2007-01-18 Betastim, Ltd. Gi and pancreatic device for treating obesity and diabetes
DE602006013995D1 (en) * 2005-07-27 2010-06-10 Qualcomm Inc SYSTEM AND METHOD FOR ONLY A FORWARD TRANSFER BIT TRANSFER LAYER
US20070027484A1 (en) 2005-07-28 2007-02-01 Cyberonics, Inc. Autonomic nerve stimulation to treat a pancreatic disorder
US7822486B2 (en) 2005-08-17 2010-10-26 Enteromedics Inc. Custom sized neural electrodes
US7551960B2 (en) * 2005-09-08 2009-06-23 Medtronic, Inc. External presentation of electrical stimulation parameters
US7620455B2 (en) 2005-10-25 2009-11-17 Cyberonics, Inc. Cranial nerve stimulation to treat eating disorders
US8041428B2 (en) 2006-02-10 2011-10-18 Electrocore Llc Electrical stimulation treatment of hypotension
EP1981584B1 (en) 2006-02-03 2015-05-13 Interventional Autonomics Corporation Intravascular device for neuromodulation
US20070191912A1 (en) * 2006-02-10 2007-08-16 Vision Quest Industries, Inc. Interactive electrical stimulator device and server-based support system
EP1984064A4 (en) 2006-02-10 2009-11-11 Electrocore Inc Methods and apparatus for treating anaphylaxis using electrical modulation
US20070233204A1 (en) * 2006-02-16 2007-10-04 Lima Marcelo G RFID-based apparatus, system, and method for therapeutic treatment of a patient
US8187297B2 (en) 2006-04-19 2012-05-29 Vibsynt, Inc. Devices and methods for treatment of obesity
US8160709B2 (en) 2006-05-18 2012-04-17 Endostim, Inc. Use of electrical stimulation of the lower esophageal sphincter to modulate lower esophageal sphincter pressure
US8068918B2 (en) 2007-03-09 2011-11-29 Enteromedics Inc. Remote monitoring and control of implantable devices
US20080300657A1 (en) 2007-05-31 2008-12-04 Mark Raymond Stultz Therapy system
EP2254462B1 (en) 2007-11-12 2015-05-20 Daniel J. Dilorenzo Apparatus for programming of autonomic neuromodulation for the treatment of obesity
US20120053653A1 (en) 2009-05-08 2012-03-01 Universite Libre De Bruxelles Gastrointestinal device
US9089708B2 (en) 2010-05-27 2015-07-28 Ndi Medical, Llc Waveform shapes for treating neurological disorders optimized for energy efficiency
AU2011282294B9 (en) 2010-07-19 2014-09-25 Cardiac Pacemakers, Inc. Minimally invasive lead system for vagus nerve stimulation
WO2012044472A2 (en) 2010-10-01 2012-04-05 Indiana University Research & Technology Corporation Long term vagal nerve stimulation for therapeutic and diagnostic treatment
US9474482B2 (en) 2010-11-01 2016-10-25 G-Tech Medical, Inc. Method for diagnosis and treatment of disorders of the gastrointestinal tract, and apparatus for use therewith
EP2635344B1 (en) 2010-11-03 2015-07-08 The Cleveland Clinic Foundation Apparatus for energy efficient stimulation

Patent Citations (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3128760A (en) * 1961-08-21 1964-04-14 Winston Electronics Ltd Vagotomy test apparatus
US4114625A (en) * 1976-12-02 1978-09-19 Onat Mustafa V Anti-vomiting, anti-aspirating oral-nasal gastric tube
US4198963A (en) * 1978-10-19 1980-04-22 Michigan Instruments, Inc. Cardiopulmonary resuscitator, defibrillator and monitor
US4867164A (en) * 1983-09-14 1989-09-19 Jacob Zabara Neurocybernetic prosthesis
US5025807A (en) * 1983-09-14 1991-06-25 Jacob Zabara Neurocybernetic prosthesis
US5236480A (en) * 1989-01-05 1993-08-17 Camfil Ab Air filter for workstations and methods of making and using such air filter
US5226426A (en) * 1990-12-18 1993-07-13 Inbae Yoon Safety penetrating instrument
US5188104A (en) * 1991-02-01 1993-02-23 Cyberonics, Inc. Treatment of eating disorders by nerve stimulation
US5199430A (en) * 1991-03-11 1993-04-06 Case Western Reserve University Micturitional assist device
US5299569A (en) * 1991-05-03 1994-04-05 Cyberonics, Inc. Treatment of neuropsychiatric disorders by nerve stimulation
US5215086A (en) * 1991-05-03 1993-06-01 Cyberonics, Inc. Therapeutic treatment of migraine symptoms by stimulation
US5335657A (en) * 1991-05-03 1994-08-09 Cyberonics, Inc. Therapeutic treatment of sleep disorder by nerve stimulation
US5226429A (en) * 1991-06-20 1993-07-13 Inamed Development Co. Laparoscopic gastric band and method
US5231988A (en) * 1991-08-09 1993-08-03 Cyberonics, Inc. Treatment of endocrine disorders by nerve stimulation
US5423872A (en) * 1992-05-29 1995-06-13 Cigaina; Valerio Process and device for treating obesity and syndromes related to motor disorders of the stomach of a patient
US5330515A (en) * 1992-06-17 1994-07-19 Cyberonics, Inc. Treatment of pain by vagal afferent stimulation
US5292344A (en) * 1992-07-10 1994-03-08 Douglas Donald D Percutaneously placed electrical gastrointestinal pacemaker stimulatory system, sensing system, and pH monitoring system, with optional delivery port
US5344438A (en) * 1993-04-16 1994-09-06 Medtronic, Inc. Cuff electrode
US5601604A (en) * 1993-05-27 1997-02-11 Inamed Development Co. Universal gastric band
US5620955A (en) * 1993-06-18 1997-04-15 Peptide Technologies Corporation Bombesin receptor antagonists and uses thereof
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US6290961B1 (en) * 1993-12-28 2001-09-18 Allergan, Inc. Method for treating dystonia with botulinum toxin type B
US6405732B1 (en) * 1994-06-24 2002-06-18 Curon Medical, Inc. Method to treat gastric reflux via the detection and ablation of gastro-esophageal nerves and receptors
US5514175A (en) * 1994-11-09 1996-05-07 Cerebral Stimulation, Inc. Auricular electrical stimulator
US6558708B1 (en) * 1995-05-17 2003-05-06 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
US5540730A (en) * 1995-06-06 1996-07-30 Cyberonics, Inc. Treatment of motility disorders by nerve stimulation
US20020055779A1 (en) * 1996-03-05 2002-05-09 Brian J. Andrews Neural prosthesis
US5747060A (en) * 1996-03-26 1998-05-05 Euro-Celtique, S.A. Prolonged local anesthesia with colchicine
US6532388B1 (en) * 1996-04-30 2003-03-11 Medtronic, Inc. Method and system for endotracheal/esophageal stimulation prior to and during a medical procedure
US20020032468A1 (en) * 1996-04-30 2002-03-14 Hill Michael R.S. Method and system for endotracheal/esophageal stimulation prior to and during a medical procedure
US6243607B1 (en) * 1996-09-05 2001-06-05 University Technologies International Inc. Gastro-intestinal electrical pacemaker
US5716385A (en) * 1996-11-12 1998-02-10 University Of Virginia Crural diaphragm pacemaker and method for treating esophageal reflux disease
US6238423B1 (en) * 1997-01-13 2001-05-29 Medtronic, Inc. Apparatus and method for treating chronic constipation
US6111715A (en) * 1997-01-13 2000-08-29 Hitachi, Ltd. Storage apparatus using a magnetoresistive head that employs a sense current selected from plural predetermined sense currents
US5861014A (en) * 1997-04-30 1999-01-19 Medtronic, Inc. Method and apparatus for sensing a stimulating gastrointestinal tract on-demand
US6083249A (en) * 1997-04-30 2000-07-04 Medtronic, Inc. Apparatus for sensing and stimulating gastrointestinal tract on-demand
US6216039B1 (en) * 1997-05-02 2001-04-10 Medtronic Inc. Method and apparatus for treating irregular gastric rhythms
US6093167A (en) * 1997-06-16 2000-07-25 Medtronic, Inc. System for pancreatic stimulation and glucose measurement
US5919216A (en) * 1997-06-16 1999-07-06 Medtronic, Inc. System and method for enhancement of glucose production by stimulation of pancreatic beta cells
US6571127B1 (en) * 1997-07-16 2003-05-27 Impulse Dynamics N.V. Method of increasing the motility of a GI tract
US20040059383A1 (en) * 1997-08-26 2004-03-25 Puskas John D. Methods of indirectly stimulating the vagus nerve with an electrical field
US20050143412A1 (en) * 1997-08-26 2005-06-30 Puskas John D. Methods of indirectly stimulating the vagus nerve with an electrical field
US6104955A (en) * 1997-12-15 2000-08-15 Medtronic, Inc. Method and apparatus for electrical stimulation of the gastrointestinal tract
US6091992A (en) * 1997-12-15 2000-07-18 Medtronic, Inc. Method and apparatus for electrical stimulation of the gastrointestinal tract
US6364899B1 (en) * 1998-01-23 2002-04-02 Innercool Therapies, Inc. Heat pipe nerve cooler
US20040089313A1 (en) * 1998-02-19 2004-05-13 Curon Medical, Inc. Systems and methods for treating obesity and other gastrointestinal conditions
US6369079B1 (en) * 1998-06-15 2002-04-09 Sepracor, Inc. Methods for treating irritable bowel syndrome using optically pure (+) norcisapride
US20020012828A1 (en) * 1998-09-07 2002-01-31 Bojidara Grigorova Fuel cell and gold-containing catalyst for use therein
US6292703B1 (en) * 1998-10-08 2001-09-18 Biotronik Mess-Und Therapiegerate Gmbh & Co. Neural electrode arrangement
US6611715B1 (en) * 1998-10-26 2003-08-26 Birinder R. Boveja Apparatus and method for neuromodulation therapy for obesity and compulsive eating disorders using an implantable lead-receiver and an external stimulator
US20050137644A1 (en) * 1998-10-26 2005-06-23 Boveja Birinder R. Method and system for vagal blocking and/or vagal stimulation to provide therapy for obesity and other gastrointestinal disorders
US6097984A (en) * 1998-11-25 2000-08-01 Medtronic, Inc. System and method of stimulation for treating gastro-esophageal reflux disease
US20020052336A1 (en) * 1999-02-26 2002-05-02 Yerxa Benjamin R. Method of treating gastrointestinal tract disease with purinergic receptor agonists
US6261280B1 (en) * 1999-03-22 2001-07-17 Medtronic, Inc Method of obtaining a measure of blood glucose
US6098629A (en) * 1999-04-07 2000-08-08 Endonetics, Inc. Submucosal esophageal bulking device
US6895278B1 (en) * 1999-04-14 2005-05-17 Transneuronix, Inc. Gastric stimulator apparatus and method for use
US6341236B1 (en) * 1999-04-30 2002-01-22 Ivan Osorio Vagal nerve stimulation techniques for treatment of epileptic seizures
US7072720B2 (en) * 1999-06-25 2006-07-04 Emory University Devices and methods for vagus nerve stimulation
US20030074039A1 (en) * 1999-06-25 2003-04-17 Puskas John D. Devices and methods for vagus nerve stimulation
US6587719B1 (en) * 1999-07-01 2003-07-01 Cyberonics, Inc. Treatment of obesity by bilateral vagus nerve stimulation
US6853862B1 (en) * 1999-12-03 2005-02-08 Medtronic, Inc. Gastroelectric stimulation for influencing pancreatic secretions
US6610713B2 (en) * 2000-05-23 2003-08-26 North Shore - Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US20020072780A1 (en) * 2000-09-26 2002-06-13 Transneuronix, Inc. Method and apparatus for intentional impairment of gastric motility and /or efficiency by triggered electrical stimulation of the gastrointestinal tract with respect to the intrinsic gastric electrical activity
US6591137B1 (en) * 2000-11-09 2003-07-08 Neuropace, Inc. Implantable neuromuscular stimulator for the treatment of gastrointestinal disorders
US20020094962A1 (en) * 2000-12-01 2002-07-18 Gary Ashley Motilide compounds
US6993391B2 (en) * 2000-12-11 2006-01-31 Metacure N.V. Acute and chronic electrical signal therapy for obesity
US6609025B2 (en) * 2001-01-02 2003-08-19 Cyberonics, Inc. Treatment of obesity by bilateral sub-diaphragmatic nerve stimulation
US20020087192A1 (en) * 2001-01-02 2002-07-04 Barrett Burke T. Treatment of obesity by sub-diaphragmatic nerve stimulation
US20020103424A1 (en) * 2001-01-31 2002-08-01 Swoyer John M. Implantable medical device affixed internally within the gastrointestinal tract
US20040127953A1 (en) * 2001-02-20 2004-07-01 Kilgore Kevin L. Systems and methods for reversibly blocking nerve activity
US6928320B2 (en) * 2001-05-17 2005-08-09 Medtronic, Inc. Apparatus for blocking activation of tissue or conduction of action potentials while other tissue is being therapeutically activated
US20050149148A1 (en) * 2001-05-17 2005-07-07 Medtronic, Inc. Apparatus and method for blocking activation of tissue or conduction of action potentials while other tissue is being therapeutically activated
US20030014086A1 (en) * 2001-07-14 2003-01-16 Sharma Virender K. Method and apparatus for electrical stimulation of the lower esophageal sphincter
US20030018367A1 (en) * 2001-07-23 2003-01-23 Dilorenzo Daniel John Method and apparatus for neuromodulation and phsyiologic modulation for the treatment of metabolic and neuropsychiatric disease
US20030040785A1 (en) * 2001-08-21 2003-02-27 Maschino Steve E. Circumneural electrode assembly
US20030045909A1 (en) * 2001-08-31 2003-03-06 Biocontrol Medical Ltd. Selective nerve fiber stimulation for treating heart conditions
US6684105B2 (en) * 2001-08-31 2004-01-27 Biocontrol Medical, Ltd. Treatment of disorders by unidirectional nerve stimulation
US20030045914A1 (en) * 2001-08-31 2003-03-06 Biocontrol Medical Ltd. Treatment of disorders by unidirectional nerve stimulation
US20030144709A1 (en) * 2002-01-25 2003-07-31 Cyberonics, Inc. Nerve stimulation as a treatment for pain
US7076307B2 (en) * 2002-05-09 2006-07-11 Boveja Birinder R Method and system for modulating the vagus nerve (10th cranial nerve) with electrical pulses using implanted and external components, to provide therapy neurological and neuropsychiatric disorders
US20050143787A1 (en) * 2002-05-09 2005-06-30 Boveja Birinder R. Method and system for providing electrical pulses for neuromodulation of vagus nerve(s), using rechargeable implanted pulse generator
US20050149146A1 (en) * 2002-05-09 2005-07-07 Boveja Birinder R. Method and system to provide therapy for obesity and other medical disorders, by providing electrical pules to symapthetic nerves or vagal nerve(s) with rechargeable implanted pulse generator
US20040039425A1 (en) * 2002-05-29 2004-02-26 Beverley Greenwood-Van Meerveld Spinal cord stimulation as treatment for functional bowel disorders
US6746474B2 (en) * 2002-05-31 2004-06-08 Vahid Saadat Apparatus and methods for cooling a region within the body
US20040086531A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc. Methods for treating ulcers and gastroesophageal reflux disease
US20050131485A1 (en) * 2003-02-03 2005-06-16 Enteromedics, Inc. High frequency vagal blockage therapy
US7167750B2 (en) * 2003-02-03 2007-01-23 Enteromedics, Inc. Obesity treatment with electrically induced vagal down regulation
US20050038484A1 (en) * 2003-02-03 2005-02-17 Enteromedics, Inc. Controlled vagal blockage therapy
US20040167583A1 (en) * 2003-02-03 2004-08-26 Enteromedics, Inc. Electrode band apparatus and method
US20060015151A1 (en) * 2003-03-14 2006-01-19 Aldrich William N Method of using endoscopic truncal vagoscopy with gastric bypass, gastric banding and other procedures
US20050049655A1 (en) * 2003-08-27 2005-03-03 Boveja Birinder R. System and method for providing electrical pulses to the vagus nerve(s) to provide therapy for obesity, eating disorders, neurological and neuropsychiatric disorders with a stimulator, comprising bi-directional communication and network capabilities
US20050070974A1 (en) * 2003-09-29 2005-03-31 Knudson Mark B. Obesity and eating disorder stimulation treatment with neural block
US20050070970A1 (en) * 2003-09-29 2005-03-31 Knudson Mark B. Movement disorder stimulation with neural block
US20050075693A1 (en) * 2003-10-02 2005-04-07 Medtronic, Inc. Driver circuitry switchable between energy transfer and telemetry for an implantable medical device
US7054690B2 (en) * 2003-10-22 2006-05-30 Intrapace, Inc. Gastrointestinal stimulation device
US20050143378A1 (en) * 2003-12-29 2005-06-30 Yun Anthony J. Treatment of conditions through pharmacological modulation of the autonomic nervous system
US20050149141A1 (en) * 2004-01-07 2005-07-07 Starkebaum Warren L. Gastric stimulation for altered perception to treat obesity
US20060036293A1 (en) * 2004-08-16 2006-02-16 Whitehurst Todd K Methods for treating gastrointestinal disorders
US20070043400A1 (en) * 2005-08-17 2007-02-22 Donders Adrianus P Neural electrode treatment

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9586046B2 (en) 2003-02-03 2017-03-07 Enteromedics, Inc. Electrode band system and methods of using the system to treat obesity
US9682233B2 (en) 2003-02-03 2017-06-20 Enteromedics Inc. Nerve stimulation and blocking for treatment of gastrointestinal disorders
US8538533B2 (en) 2003-02-03 2013-09-17 Enteromedics Inc. Controlled vagal blockage therapy
US9174040B2 (en) 2003-02-03 2015-11-03 Enteromedics Inc. Nerve stimulation and blocking for treatment of gastrointestinal disorders
US7693577B2 (en) 2003-02-03 2010-04-06 Enteromedics Inc. Irritable bowel syndrome treatment
US7720540B2 (en) 2003-02-03 2010-05-18 Enteromedics, Inc. Pancreatitis treatment
US7729771B2 (en) 2003-02-03 2010-06-01 Enteromedics Inc. Nerve stimulation and blocking for treatment of gastrointestinal disorders
US9162062B2 (en) 2003-02-03 2015-10-20 Enteromedics Inc. Controlled vagal blockage therapy
US7844338B2 (en) 2003-02-03 2010-11-30 Enteromedics Inc. High frequency obesity treatment
US8010204B2 (en) 2003-02-03 2011-08-30 Enteromedics Inc. Nerve blocking for treatment of gastrointestinal disorders
US8046085B2 (en) 2003-02-03 2011-10-25 Enteromedics Inc. Controlled vagal blockage therapy
US8538542B2 (en) 2003-02-03 2013-09-17 Enteromedics Inc. Nerve stimulation and blocking for treatment of gastrointestinal disorders
US8103349B2 (en) 2005-08-17 2012-01-24 Enteromedics Inc. Neural electrode treatment
US7672727B2 (en) 2005-08-17 2010-03-02 Enteromedics Inc. Neural electrode treatment
US11413296B2 (en) 2005-11-12 2022-08-16 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20080281365A1 (en) * 2007-05-09 2008-11-13 Tweden Katherine S Neural signal duty cycle
US20180325921A1 (en) * 2007-11-13 2018-11-15 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20160235769A1 (en) * 2007-11-13 2016-08-18 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US9186502B2 (en) 2008-02-14 2015-11-17 Enteromedics Inc. Treatment of excess weight by neural downregulation in combination with compositions
US20090210019A1 (en) * 2008-02-14 2009-08-20 Dennis Dong-Won Kim Treatment of excess weight by neural downregulation in combination with compositions
US9974955B2 (en) 2008-04-04 2018-05-22 Reshape Lifesciences Inc. Methods and systems for glucose regulation
US20090254143A1 (en) * 2008-04-04 2009-10-08 Tweden Katherine S Methods and systems for glucose regulation
US10722714B2 (en) 2008-04-04 2020-07-28 Reshape Lifesciences, Inc. Methods and systems for glucose regulation
US8483830B2 (en) 2008-04-04 2013-07-09 Enteromedics Inc. Methods and systems for glucose regulation
US8825164B2 (en) 2010-06-11 2014-09-02 Enteromedics Inc. Neural modulation devices and methods
US9358395B2 (en) 2010-06-11 2016-06-07 Enteromedics Inc. Neural modulation devices and methods
US9968778B2 (en) 2010-06-11 2018-05-15 Reshape Lifesciences Inc. Neural modulation devices and methods

Also Published As

Publication number Publication date
US8538542B2 (en) 2013-09-17
EP2366425A1 (en) 2011-09-21
US20040172085A1 (en) 2004-09-02
US20040176812A1 (en) 2004-09-09
US7489969B2 (en) 2009-02-10
US20040172084A1 (en) 2004-09-02
US9682233B2 (en) 2017-06-20
US20170304615A1 (en) 2017-10-26
DK1601414T3 (en) 2012-05-29
US20080021512A1 (en) 2008-01-24
US9174040B2 (en) 2015-11-03
US20140172052A1 (en) 2014-06-19
US8010204B2 (en) 2011-08-30
US7729771B2 (en) 2010-06-01
AU2009245845B2 (en) 2011-09-29
US20160193465A1 (en) 2016-07-07
US20040172086A1 (en) 2004-09-02
AU2009245845A1 (en) 2010-01-07
ATE547148T1 (en) 2012-03-15
US20100168815A1 (en) 2010-07-01
ATE537871T1 (en) 2012-01-15
US20110282411A1 (en) 2011-11-17

Similar Documents

Publication Publication Date Title
US20060229685A1 (en) Method and apparatus for treatment of gastro-esophageal reflux disease (GERD)
EP1601414B1 (en) Apparatus for neural stimulation
US7937144B2 (en) Electric modulation of sympathetic nervous system
US9037244B2 (en) Method and apparatus for electrical stimulation of the pancreatico-biliary system
US7236822B2 (en) Wireless electric modulation of sympathetic nervous system
US7689276B2 (en) Dynamic nerve stimulation for treatment of disorders
US7702386B2 (en) Nerve stimulation for treatment of obesity, metabolic syndrome, and Type 2 diabetes
US8295926B2 (en) Dynamic nerve stimulation in combination with other eating disorder treatment modalities
US20080262411A1 (en) Dynamic nerve stimulation in combination with other eating disorder treatment modalities
CA2639996A1 (en) Nerve stimulation for treatment of obesity, type 2 diabetes, and metabolic syndrome
Mizrahi et al. Gastric stimulation for weight loss

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: RESHAPE LIFESCIENCES INC., CALIFORNIA

Free format text: CHANGE OF NAME;ASSIGNOR:ENTEROMEDICS INC.;REEL/FRAME:045949/0495

Effective date: 20171012